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p63, a p53 family member, is a transcription factor that has complex roles in cancer. This study 
focuses on the role of the ∆Np63α isoform in bladder cancer (BC). Epithelial – mesenchymal 
transition (EMT) is a physiological process that plays an important part in metastasis and drug 
resistance. At the molecular level, EMT is characterized by the loss of the epithelial marker E-
cadherin, and the acquisition of the transcriptional repressors of E-cadherin (ZEB1, ZEB2, 
TWIST, SNAI1 and SNAI2). Recent publications highlight the role of microRNAs belonging 
to the miR-200 family and miR-205 in preventing EMT through suppression of ZEB1 and 
ZEB2. p53, the homologue of p63, is implicated in regulating EMT by modulating the 
expression of miR-200c; however, the mechanisms underlying miR-205 control remain 
unclear. Here we show that ∆Np63α regulates the transcription of miR-205 and controls EMT 
in human BC cells. We observed a strong correlation between the expression of ∆Np63α, miR-
205 and E-cadherin in a panel of BC cell lines (n=28) and also in bladder primary tumors from 
vii 
 
a cohort of patients (n=98). A remarkably inverse correlation is observed between ∆Np63α and 
ZEB1/2 in cell lines. Stable knockdown (KD) ∆Np63α in UC6, an “epithelial” BC cell line, 
decreased the expression of miR-205 and induced ZEB1/2 expression, the effects that were 
reversed by expression of exogenous miR-205. Moreover, overexpressing ∆Np63α in UC3, a 
“messenchymal” BC cell line, brought about opposite results, an increase in miR-205 
expression and a reduction in ZEB1/2 expression. Modulation of ∆Np63α expression resulted 
in a parallel change in the expression of miR-205 and miR-205 “host” gene (miR-205HG). 
Nuclear run-on and chromatin immunoprecipitation experiments demonstrated that ∆Np63α 
regulates the transcription of miR-205 through controlling the recruitment of RNA Polymerase 
II to the promoter of miR-205HG. Interestingly, high miR-205 expression correlated with poor 
clinical outcome in BC patients, consistent with our recent publication highlighting the 
enrichment of ∆Np63 in a lethal subset of muscle invasive BC. 
In summary, our data present the important roles of ∆Np63α in preventing EMT mediated by 
miR-205. Our study also identifies miR-205 as a potential molecular marker to predict clinical 
outcome in BC patients. 
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1. EPITHELIAL-MESENCHYMAL TRANSITION (EMT) – MESENCHYMAL-
EPITHELIAL TRANSITION (MET) – CANCER PLASTICITY 
1.1. General introduction 
Epithelial – mesenchymal transition (EMT) is a reversible biological process in which 
epithelial cells lose some of their epithelial characteristics including the apico-basolateral 
polarity, rigid structure, and cell-cell and cell-basement membrane adhesion, and assume 
properties of mesenchymal cells including flexible structure and enhanced migratory and 
invasive capacity. EMT involves multiple molecular processes such as down regulation of 
adhesion molecules via activation of an EMT-related transcription factor circuit, modulation of 
microRNA expression, reorganization of cytoskeletal proteins, and production of extracellular 
matrix (ECM) degrading enzymes (1,2). Well characterized molecules associated with the 
epithelial (E) and mesenchymal (M) phenotype that have been widely used as E and M markers 
for EMT research are listed in Fig. 1. The majority of E markers are molecules participating in 
maintaining the epithelial phenotype such as cell junction molecules (E-cadherin, ZO-1, 
desmoplakin), cytoskeletal proteins (cytokeratins), and molecules mediating cell-extracellular 
matrix interaction (entactin, collagen). M markers are more variable in functions but they all 
suppress the epithelial phenotype and promote messenchymal phenotype. Transcription factors 
(ZEB1, ZEB2, SNAI1, SNAI2, and TWIST) and microRNAs (miR-10b, miR-21) involved in 
regulating the expression of adhesion molecules are considered as M markers. Besides, 
cytoskeletal proteins and cell-ECM interaction proteins that are specific for mesenchymal cells 
are also M markers, such as vimentin, fibronectin, N-cadherin, and α5β1 integrin.  
 The reverse process of EMT, mesenchymal-epithelial transition (MET), which involves 
the reversion of mesenchymal cells to epithelial cells, has been documented in normal 
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development processes such as kidney development (3,4) and hepatogenesis (5). However, 
information regarding MET is still limited. 
1.2. Classification of EMT 
EMT was discovered in three different biological settings with distinct functional 
consequences. Based on the biological context, EMT was classified into three subtypes. Type 1 
EMT occurs in implantation, embryogenesis and organ development. The EMT happening later 
in life and involved in wound healing, tissue regeneration and organ fibrosis is the second type. 
Type 3 EMT is associated with cancer progression and metastasis (1) (Fig. 2). 
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Figure 1: Epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial 
transition (MET). Common markers for epithelial cells and mesenchymal cells are listed in 
orange and green, respectively. Colocalization of both epithelial and mesenchymal markers 
presents in cells in the transition state. This intermediate phenotype indicates that cells have 
passed only partly through either EMT or MET process. ZO-1, zona occludens 1; MUC1, 
mucin 1, cell surface associated; miR200, microRNA 200; SIP1, survival of motor neuron 
protein interacting protein 1; FOXC2, forkhead box C2. Adapted from Kalluri, R. et al., J Clin 
Invest 119, 1420-1428 (2009) with permission from Journal of Clinical Investigation. 
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Type 1 EMT: 
During implantation, when the blastocyst attaches to the uterine wall, the trophoblast 
undergoes EMT, acquiring the invasive capacity to invade through the epithelial lining of the 
uterus – the uterine endometrium - allowing the blastocyst to embed in the underlining tissue 
(6,7). Once properly localized in the endometrial stroma, the blastocyst proceeds to gastrulation 
to generate three germ layers: ectoderm, mesoderm and endoderm. The embryoblast has 
already developed into a two layer structure: a layer of columnar cells, called epiblast, lining 
the amniotic cavity and a layer of cells, called hypoblast, lining the primary yolk sac. Via 
furrowed invagination in the midline of the epiblast layer, the primitive streak is formed, 
marking the initial step of gastrulation. The epithelial-like epiblast cells experience molecular 
changes that induce expression of proteins associated with migration and differentiation to 
facilitate the primitive streak formation (8,9). Via EMT, epiblast cells invaginate into the space 
between epiblast and hypoblast and generate mesendoderm which subsequently separates to 
form mesoderm and endoderm by replacing hypoblast cells (10). The epiblast cells that remain 
in the original epiblast layer become ectoderm (Fig. 2.A).  
Type 1 EMT also happens during neurulation. When the neural plate fold along its 
central axis, a neural groove is formed and lined on each side by a neural fold. Two neural folds 
fuse together in a zipper-like manner and pinch off to form neural tube. The neural crest cells, 
originated from the neural folds, undergo EMT and migrate throughout the embryo and 
differentiate into multiple cell types, among which are the melanocytes (11-13).  
Type 2 EMT 
Type 2 EMT occurs in adult tissue and plays a crucial role in wound healing, tissue 
regeneration and organ fibrosis. This type of EMT is associated with inflammation. It occurs in 
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response to inflammatory signal and ceases when inflammation is diminished (1). In wound 
healing, fibroblasts generated from the epithelial cells in the adjacent tissue via EMT migrate 
and proliferate across the wound site, participating in the formation of granulation tissue that 
continues to grow until the wound bed is covered (14,15). Fibroblasts secrete multiple 
components of the extracellular matrix (ECM), such as fibronectin, collagens, elastins, laminin 
and tenacins, to support their migration and the attachment of cells involved in inflammation, 
angiogenesis, and connective tissue construction (16). During the re-epithelialization step of the 
cutaneous wound healing process, keratinocytes lose cell-cell adhesion and gain migratory 
capacity via an EMT-like process to migrate across the new tissue and seal the wound (17). 
Once wound healing finish, inflammatory signals are attenuated, and EMT is halted.  
Organ fibrosis is the formation of excess fibrous connective tissue that eventually leads 
to tissue destruction. Organ fibrosis is a form of wound healing that is unabated due to 
persistent inflammation. In the setting of organ fibrosis, inflammatory cells and fibroblasts 
release a variety of inflammatory signals to trigger EMT. This type of EMT was identified in 
fibrosis of the kidney, liver, lung and intestine (18-20). Particularly, during kidney fibrosis in 
mice, about 30% of fibroblasts arise from the tubular epithelial cells via EMT (21). Growth 
factors (TGF-β, PDGF, EGF, and FGF-2), chemokines and MMPs (MMP-2, MMP-3, MMP-9) 
are secreted from a various type of cells, prominently macrophages and activated resident 
fibroblasts, due to inflammation (22). Under the influence of these molecules, together with 
inflammatory cells, epithelial cells degrade the basement membrane, lose their polarity and 
migrate into the interstitial area following a gradient of the signals. This process, which is 
characterized by multiple molecular markers, happens through sequential steps in which 
epithelial cells gradually shed their epithelial phenotype and accumulate mesenchymal traits. 
Concomitant expression of epithelial markers (E-cadherin, cytokeratins) and mesenchymal 
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markers (vimentin, desmin, DDR-2, FSP-1 and α-SMA) are identified in cells in the transition 
process. These cells present the intermediate phenotypes, generating the notion of “partial 
EMT”. Identification of such cells demonstrates that epithelial cells can advance to various 
extents through an EMT. Eventually, when these cells completely pass through the basement 
membrane and locate in the interstitium of the tissue, they shed all of their epithelial markers as 
well as their epithelial morphology and gain fully mesenchymal markers and fibroblast shape 
(23) (Fig. 2.B). 
Type 3 EMT 
Besides tissue fibrosis, the pathological aspect of EMT is revealed in cancer progression 
and metastasis. This type of EMT is classified as type 3. Uncontrolled proliferation, the 
capacity to evade apoptosis and angiogenesis are well characterized as some of the hallmarks of 
cancer cells. These characteristics provide cancer cells the growth advantage to setup the tumor 
bulk at the primary site (24). Subsequently, cancer cells intravasate into the blood vessels, 
follow the blood circulation, extravasate, form micrometastases at distant organ and finally 
colonization to establish macrometastases, completing the multistep process of metastasis with 
lethal consequence (25). Multiple studies have been focusing on the metastasis cascade and 
many of these studies suggest the crucial role of EMT in providing the epithelial cancer cells 
the invasive capacity and, to a certain extent, stem-like characteristics to survive the blood 
circulation and drug treatment (1,26). Cancer cells at the invasive front present mesenchymal 
phenotype and mesenchymal markers such as α-SMA, FSP-1, vimentin, and desmin, indicating 
that they have undergone EMT (1). These mesenchymal cells can enter the blood vessels and 
complete the metastasis cascade.  
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Figure 2: Three different types of EMT. (A) Type 1 EMT happens in embryonic gastrulation. 
Epiblast cells invaginate along the primitive streak and give rise to primary mesenchyme via 
EMT. (B) Type 2 EMT occurs in adult tissue in response to inflammation in wound healing 
process or in organ fibrosis. Prolonged inflammatory signals can result in organ destruction. 
(C) Type 3 EMT presents in cancer progression, providing cancer cells migratory and invasive 
capacity to metastasize. Reprinted from Kalluri, R. et al., J Clin Invest 119, 1420-1428 (2009) 
with permission from Journal of Clinical Investigation. 
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However, it is well documented that distant metastases histopathologically resemble the 
primary tumors, and no longer display mesenchymal phenotype but exhibit epithelial 
characteristics. An explanation for this paradoxical observation is the reversibility of EMT. The 
absence of EMT-triggering signals in the distant organs induces disseminated cancer cell to 
experience MET, the reverse process of EMT, to shed their mesenchymal traits and acquire 
their original epithelial phenotype (27-29). These considerations emphasize the importance of 
EMT in tumor invasion and metastasis as well as the crucial role of MET in subsequent 
colonization at distant organ. Multiple studies have been designed to understand EMT and 
MET in tumor progression and metastasis. So far, multiple signaling pathways involved in 
EMT activation, EMT markers, and other aspect of EMT, such as drug resistance and 
“stemness”, have been identified. This knowledge promises clinical implications in the near 
future (Fig. 2.C).  
1.3. EMT in cancer 
Mechanism of EMT activation 
Typically, EMT is determined by the loss of the epithelial markers and the acquisition 
of the mesenchymal markers. Popular epithelial markers used in EMT studies are cell adhesion 
molecules, such as E-cadherin, plakophilins, desmoplakin, PAR6, occludin, and claudins, 
cytoskeletal proteins, such as CK8, CK18, and CK19 (30), and cell polarity protein 
(PAR6(31)). Mesenchymal markers that have been reported in EMT are the transcriptional 
repressors of E-cadherin (ZEB1, ZEB2, TWIST, Snail, and Slug). These repressors directly 
bind to E-box elements located within the proximal E-cadherin promoter and suppress E-
cadherin transcription (32). MicroRNAs are also key players of EMT. Members of the miR-200 
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family and miR-205 inhibit EMT by binding to 3‟UTRs of ZEB1/2, repressing the expression 
of ZEB1/2‟s transcripts and, as a result, induce E-cadherin expression (33-36). 
Signaling pathways 
EMT is generally triggered by extracellular signals secreted by the mesenchymal cells 
in the stroma (2). The best characterized EMT inducers are members of the transforming 
growth factor-β (TGF β) family. The canonical TGFβ signaling pathway starts with the 
formation of the heterogenic complex of type I and type II transmembrane serine-threonin 
kinase receptors in response to TGF-b ligand binding (37,38). Activated TGFβRII 
phosphorylates TGFβRI which subsequently phosphorylates Smad2 and Smad3 at their C-
termini (37,38). Phosphorylated Smad2/3 partner with cytoplasmic Smad4 and translocate into 
the nucleus, where they regulate transcription of multiple targets among which are crucial EMT 
players including SNAI1/2, ZEB1/2, E12/E47, TWIST, Ids (37,38). Obstruction of TGFβ 
signaling at any point of the cascade blocks EMT and promotes the epithelial phenotype 
(37,38). TGFβ can activate EMT through a Smad independent pathway. In mammary epithelial 
cells, TGFβII interacts with and phosphorylates PAR6, an important regulator of cell polarity 
and tight junction. Phosphorylated PAR6 interacts with the E3 ubiquitin ligase Smurf1, which 
in turn targets RhoA, a small GTPase protein regulating the assembly of focal adhesions and 
actin stress fibers, leading to RhoA degradation and subsequently, loss of tight junction and 
apical-basal polarity (31). TGFβ also promotes EMT by cooperating with other signaling 
pathways such as Wnt, Notch, MAPK and integrin signaling in a cell-context dependent 
manner.  
Wnt signaling can trigger EMT by itself or in cooperation with TGFβ signaling. In the 
absence of Wnt, cytoplasmic β-catenin is phosphorylated by glycogen synthase kinase - 3β 
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(GSK3β) at its N-terminal domain. Phosphorylated β-catenin is then rapidly ubiquitinated by an 
E3 ubiquitin protein complex containing F-box protein β-Trcp1 and subject to proteasome-
mediated degradation. When Wnt signaling is activated, GSK3β is inhibited, leading to 
cytoplasmic β-catenin accumulation, allowing β-catenin to partner with TCF or LEF, two 
related transcription factors, and translocate to the nucleus where they regulate transcription of 
multiple targets among which are EMT players (39,40). β-catenin/TCF4 has been shown to 
directly bind to the promoter and activate the transcription of ZEB1, which induces the 
expression of pro-invasive markers MT1-MMP and LAMC2 in colorectal cancer (41). Wnt 
signaling also can activate EMT markers independent of β-catenin. Wnt/GSK3β/β-trcp1 axis 
blocks Snail and Slug phosphorylation, preventing their ubiquitin-dependent proteasome-
mediated degradation and inducing EMT (42,43). Convergence of multiple TGFβ signaling and 
Wnt signaling molecule confers EMT. Snail and Slug promote the formation of β-catenin-
TCF4 complexes which induce the transcription of TGFβ3. TGFβ3 in turn activates the TGFβ 
signaling and increases LEF1 transcription, triggering the formation of β-catenin-LEF1 
complexes which are responsible for EMT initiation. TGFβ1 and TGFβ2 are also involved in 
signaling mechanism by up-regulating the expression of Snail and Slug (44). 
Notch and Hedgehog are the two other developmental pathways involved in EMT(45). 
Notch is one of a few signaling pathway that acts in a localized manner. Upon contact with the 
ligands on the membrane of neighboring cells, the transmembrane Notch receptors are cleaved 
at two domains (46). The first proteolytic cleavage is at its extracellular domain by tumour 
necrosis factor-alpha(TNFα)-converting enzyme (TACE) - a protease of the ADAM family, 
and the second one is at its intracellular domain by the γ-secretase complex to release the NIC 
(Notch intracellular domain) (46). NIC enter the nucleus, associates with the transcription 
repressor complex C protein binding factor 1/Suppressor of Hairless/Lag-1 (CSL), inducing the 
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dislocation of co-repressors (CoRs) and recruitment of the co-activators (CoAs) such as 
Mastermind to activate the transcription of Notch‟s target genes including the HES/HEY family 
(46). The Notch pathway plays crucial roles in embryonic development. Notch is also involved 
in tumorigenesis, cancer progression and metastasis; however, the outcome of Notch is cell-
type dependent and can either be oncogenic or tumor suppressive (45). Notch is reported to 
suppress E-cadherin transcription by directly activating the transcription of Snail and Slug, thus 
inducing EMT. Cross-talk between Notch and TGFβ signaling as well as between Notch and 
receptor tyrosine kinase (RTK) signaling such as FGF, PDGF to regulate EMT are also 
documented (47,48). Similar to Notch, Hedgehog signaling regulates important aspects of 
developmental biology and cancer biology. Members of Hedgehog signaling pathway are 
involved in proliferation, cell-fate determination, and stemness. Cooperation between 
Hedgehog signaling and Wnt, EGF/FGF and/or TGFβ signaling promotes EMT through E-
cadherin suppression (49). As a result, it appears that signaling pathways regulating stem cell 
functions are also involved in EMT, suggesting an activation of a stem cell program during 
EMT. 
Multiple RTKs plays important roles in EMT happening in embryogenesis (9,50). 
Mutations of RTKs have been reported in various types of cancer. Beside their impacts on all 
the hallmarks of cancer such as proliferation, apoptosis, angiogenesis, RTK signaling also 
activates EMT via enhancing expression of E-cadherin suppresors (Snail and Slug) and 
molecules involved in adhesion and cytoskeletal organization (Rac and Rho)(51).  
Integrins are transmembrane receptors that mediate the attachment between cells and 
the neighboring cells or between cells and the ECM. Cell motility depends mainly on the focal 
adhesion formed by integrin and other cytoplasmic proteins to connect the cytoskeleton and 
ECM components. As a result, in addition to disrupting cell-cell adhesion, cells undergoing 
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EMT also regulate their interaction with ECM mediated by integrins. Integrin-link kinase 
(ILK), an intracellular protein that interacts with the cytoplasmic domain of integrins, is a key 
component of focal adhesion. ILK can downregulate E-cadherin and is involved in TGFβ-
mediated EMT (9). 
Hypoxia and tumor-stroma interaction 
Hypoxia is one physiological condition that triggers EMT through multiple mechanisms 
(2,52). Hypoxia impact on cancer progression and metastasis is mediated mainly by stabilized 
hypoxia inducible factors (HIFs) (52). HIFs are transcription factors some of whose 
downstream targets are EMT markers including TWIST, Snail, Slug, ZEB1, and ZEB2. 
Hypoxic conditions also activate and maintains major EMT pathways such as TGFβ, Notch, 
and NF-κB. Coss-talk between HIF and TGFβ pathway aids in sustaining the activation status 
of TGFβ signaling and the stabilization of HIF, thus stabilizing the mesenchymal state of cells 
located at the hypoxic areas (52). In addition, hypoxia induces recruitment of inflammatory 
cells which secreting inflammatory cytokines such as TNFα, TGFβ, IL-1, IL-6 and IL-8. These 
cytokines are known as EMT inducing factors (52). Hypoxia-activated EMT provides and 
explanation for the well-established association between hypoxia and tumor progression and 
metastasis (reviewed in (52)). 
Since EMT activating factors are mostly secreted by cells in the tumor surrounding 
stroma, increased expression of mesenchymal markers localizes at the cancer cells at the tumor-
stroma interface which is also the invasive front of an aggressive tumor. This was demonstrated 
in many cancer types in human tumor samples as well as in animal models (53-55). 
Genetic and epigenetic control 
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Genetic and epigenetic instabilities are well known as hall marks of cancer. Mutation 
and aberrant expression of crucial genes are the source of tumorigenesis, tumor progression and 
metastasis. Mutation and abnormal epigenetic control of CDH1gene leading to stable loss of E-
cadherin have been reported in many tumors (56). Especially CDH1 mutation is identified as a 
cause of hereditary diffuse gastric cancer (56,57). Loss of E-cahderin due to DNA 
hypermethylation within the promoter region of CDH1 is more commonly found in cancer and 
is associated with tumor progression and metastasis (56,58).  Similar to CDH1, genes encoding 
epithelial markers including miR-200 family, miR-205(59,60), and miR-34c(61) are methylated 
in breast and lung cancer. An alternative mechanism of EMT activation in cancer is DNA 
hypomethylation of genes inducing the mesenchymal phenotype. DNA methylation profiles of 
stem-like cells CD44
+
/CD24
- 
of breast cancer reveal a hypomethylated status of a number of 
genes regulating stem cell functions and EMT, leading to an enhanced expression of these 
genes in stem-like tumor-intitiating cell enriched CD44
+
/CD24
- 
 subpopulation compared to the 
more differentiated CD44
-
/CD24
+ 
group. These hypomethylation profiles are also associated 
with an increased risk of metastasis in patients (62). Interestingly, inactivation of miR-205 and 
miR-200 via DNA hypermethylation associated with EMT and stem-like properties are induced 
during malignant transformation of human lung epithelial cells in response to tobacco 
carcinogen exposure (59). These studies highlight the alliance between EMT and stemness in 
cancer.  
Transcriptional control 
A group of transcription factors including ZEB1, ZEB2 (also known as SIP1), SNAI1 
(also known as Snail), SNAI2 (also known as Slug), TWIST, FOXC1, FOXC2, E47 (also 
known as E2α) are identified as EMT inducers in embryonic development and various types of 
cancer. All of these transcription factors directly or indirectly repress E-cadherin expression. 
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ZEB1/2 are two well characterized direct repressors of E-cadherin. ZEB1 (formerly known as 
δEF1) and ZEB2 (SIP1) belong to the ZEB transcription factor family. ZEB1/2 possess two 
zinc finger cluster at each ends and a homeodomain at the center. Via their zinc finger domains, 
ZEB1/2 bind to bipartite E-box (CACCT and CACCTG) on promoters of its target genes. 
Depending on the downstream targets, ZEB1/2 activates or represses transcription by recruiting 
the co-activators (PCAF or p300) or co-repressors (CTBP), respectively (32). ZEB1 binds to 
the E-box sequence on E-cadherin promoter and suppresses transcription of E-cadherin 
together with CtBP in breast cancer (63,64). Recently, ZEB1 has been shown to repress E-
cadherin expression by recruiting the SWI/SNF chromatin remodeling protein BRG1 and 
inducing EMT in colorectal carcinoma (65). In response to TGFβ signals, ZEB1 and ZEB2 
collaborate with each other to repress E-cadherin and promote the mesenchymal phenotype 
(66).  
Besides E-Cadherin, the EMT promoting transcription repressors also share some 
common targets as well as act independently on a subset of EMT-related genes. Their targets 
are genes encoding cell junction proteins such as cadherins, plakoglobin (adhesion junction), 
claudins, occludin and ZO proteins (tight junction), integrins (cell-ECM junction), and 
cytoskeletal proteins such as cytokeratins. Cross talk between these EMT transcription factors 
generates a complex signaling network to suppress epithelial traits and maintain the 
mesenchymal phenotype. 
microRNAs (miRNAs) in EMT 
The discovery of non-coding RNAs reveals a whole new aspect of gene expression 
control that is implicated in all cellular process. The importance of non-coding RNAs, 
especially microRNAs, in EMT has been reported in many studies. The miR-200 family (miR-
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200a/b/c, miR-141 and miR-429) and miR-205 are described as negative regulators of E-
cadherin repressors in two independent studies in 2008 (33,35,67). These microRNAs target 
ZEB1/2, promote E-cadherin expression and inhibit EMT. By examining the expression of 207 
miRNAs in 60 cancer cell lines from National Cancer Institute, Park et al. discovered the 
strong correlation between miR-200 family members and E-cadherin and the significant inverse 
correlation between miR-200 family and vimentin. In vitro experiments showed that miR-200 
family represses ZEB1/2 mRNA expression, thus promoting the expression of E-cadherin and 
suppresses vimentin. Interestingly, introducing exogenous miR-200 or inhibiting endogenous 
miR-200 results in MET or EMT respectively (67). In another study, Gregory PA. et al. 
revealed that miR-200 family and miR-205 were down regulated in response to EMT induced 
by TGFβ and that enforced expression of miR-200 family alone can prevent TFGβ-induced 
EMT (33). This group described in detail the binding sites of miR-200 family and miR-205 on 
the 3‟ UTR of ZEB1/2 and demonstrated the importance of these miRNAs in ZEB1/2‟s 3‟UTR 
expression by luciferase assay. Similar to the publication by Park S. et al.(67), they showed that 
miR-200 family and miR-205 maintain E-cadherin expression and the epithelial phenotype by 
targeting ZEB1/2. The clinical importance of this finding was illustrated in breast cancer, in 
which loss of the miR-200 family was identified in metaplastic regions lacking E-cadherin, 
indicating that downregulation of these epithelial miRNAs may participate in tumor 
progression (33). Recently, p53 is identified as a transcriptional regulator of miR-200c, one of 
the “epithelial” miRNAs (68), shedding initial light to the transcriptional control of EMT-
related miRNAs. In contrast to miR-200 and miR-205, miR-10b is an inducer of invasion and 
metastasis in breast cancer (69). By inhibiting translation of the homeobox D10 (HOXD10) 
mRNA, miR-10b indirectly accelerates the expression of a well-known pro-metastatic gene 
RHOC which is represses by HOXD10 (69). Consisting with the in vitro data demonstrating 
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miR-10b positively regulate migration and invasion, the expression of miR-10b in primary 
breast cancer samples correlates with progression (69). 
1.4. EMT and stemness  
There are multiple evidences indicating the close relationship between EMT and 
stemness. The majority of the EMT activating signaling pathways such as Notch, Wnt, 
Hedgehog, and TGFβ are involved in regulating stem cell functions and niche-stem cells 
interactions. Misregulation of these EMT activating signaling pathways is found in multiple 
types of solid tumors. Recently, a large body of cancer research supports the “Cancer Stem 
Cells” hypothesis which classifies tumor cells into two groups: Cancer Stem Cells (CSCs) or 
tumor-initiating cells and non-CSCs. CSCs possess stem-like properties such as self-renewal 
and differentiation to form various types of non-CSC. CSCs are responsible for tumor 
initiation, drug resistance and metastasis (70). Interestingly, the emergence of CSCs is 
indicated as a consequence of EMT induced by signals from the tumor microenvironment (71). 
Mani S. et al demonstrated that EMT generates stem cell properties in normal and transformed 
mammary cells. EMT induction, either by over expression Snail or TWIST or TGFβ treatment 
in nontumorigenic, immortalized human mammary epithelial cells (HMLEs) generates 
mesenchymal cells with CD44
high
/CD24
low
 antigen phenotype which is well-established as 
neoplastic mammary stem cells markers and enhanced mammosphere formation capacity. 
Consistently, stem-like CD44
high
/CD24
low
 HMLEs cells, normal primary mouse mammary  
stem cells, primary normal and malignant human stem-like CD44
high
/CD24
low
 cells express a 
number of canonical EMT markers including high N-cadherin, Vimentin, Snail, Slug, TWIST, 
ZEB2, FOXC2 and low E-cadherin (72). In addition, an enrichment pattern of gene expression 
associated with embryonic stem cells was discovered in a poorly differentiated and aggressive 
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subset of tumors in various types of cancer (73). In summary, these publications highlight the 
connection between EMT, stemness and adverse clinical outcome in cancer.  
1.5. Partial EMT-MET-cancer plasticity and metastasis  
Since EMT and MET are reversible processes, the epithelial (E) and mesenchymal (M) 
phenotypes are changeable. Various intracellular signaling pathways triggered by extracellular 
signals are involved in EMT and MET. Cross-talk among these pathways in cancer cells 
generates a complex signaling networks in which a fine-tuned change in expression of critical 
EMT players determine the E or M phenotype (9,32). Due to the genetic and epigenetic 
instability of cancer, EMT as well as any other processes in cancer cells are highly dynamic, 
providing cancer cells the plasticity to adapt to the surrounding environment, develop and 
metastasize. Activation of EMT in cancer cells at the primary tumor site facilitates invasion and 
dissemination; once cancer cells reach the distant site, activation of MET to revert the 
mesenchymal metastasizing cancer cells to the epithelial phenotype is crucial for 
macrometastasis formation. This hypothesis was clearly attested in the skin carcinogenesis in 
vivo model by Tsai J. et al (74). They developed a transgenic mouse model carrying an 
inducible TWIST1 construct that is only expressed at the basal epidermal layer upon 
doxycycline (dox) treatment. After skin squamous cell carcinoma formation in response to 
7,12-dimethylbenz[a]anthracene (DMBA) treatment followed by weekly applications of 12-O-
tetradecanoylphorbol-13-acetate (TPA), TWIST1 was activated either locally at the primary 
tumor site by dorsal dox injection – the “reversible EMT” model - or systemically throughout 
the body by dox addition drinking water – the “irreversible EMT” model. Interestingly, the 
reversible EMT model is significantly more efficient in generating distant metastases than the 
irreversible EMT model. The role of EMT was also experimentally examined in each step of 
the metastasis process. Their results showed that EMT activation promotes tumor cell 
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intravasation and extravasation; however, reversion of EMT is crucial for colonization in 
distant sites (74). Even though circulating tumor cells (CTC) have EMT signature (low E-
cadherin, high TWIST1, high Vimentin), they also express high Cytokeratins (74-76), E 
markers, indicating that carcinoma cells in vivo may only need to undergo “partial EMT” for 
dissemination. This partial EMT phenotype, which is also reported in organ fibrosis, may be 
sufficient to promote invasion and dissemination; moreover, it also provides the metastasizing 
cancer cell the ability to quickly revert to the epithelial phenotype to proliferate and develop 
macrometastases.  
In summary, in vitro experiments demonstrating cancer cells shed their epithelial 
phenotype and acquire mesenchymal traits when they undergo EMT could be misleading when 
applied to explain metastasis in patients. The partial EMT phenotype representing the 
intermediate status of EMT is possibly more common in metastasizing cancer cells in patients. 
 
2. MICRORNA 
MicroRNAs (miRNAs) are small (19-23 nucleotides) non-coding RNAs involved in 
regulating gene expression (77). After being transcribed, the primary form of miRNAs (pri-
miRs) undergoes a multistep maturation process to form precursor miRNAs (pre-miRs) and 
finally mature miRNA which associates with Argonaute (Ago) proteins to form the RNA-
induced silencing complex (RISC), a ribonucleoprotein complex, to mediate post 
transcriptional gene silencing. miRNAs guide RISC to their targets by complementary base 
pairing to the target mRNA, promoting mRNA degradation or blocking translation. Due to its 
short sequence, a single miRNA can have multiple targets, highlighting the importance of 
miRNAs in gene regulation that affect all functional aspects of cells. Deregulation of miRNA 
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biogenesis leading to abnormal expression of miRNA participates in many aspects of cancer 
including proliferation, apoptosis, EMT, invasion and metastasis (78,79). 
2.1. Transcription of pri-miRNAs 
Similar to messenger RNA (mRNA), microRNAs are transcribed inside the nucleus by 
either RNA Polymerase II (Pol II) or RNA Polymerase III (Pol III) to form long primary 
transcripts (pri-miRNAs). There are evidences proving that majority of pri-miRNAs are 
transcribed by Pol II; for instance many pri-miRNAs are polyadenylated and capped and pri-
miRNA transcription is sensitive to treatment with the Pol II inhibitor α-amanitin (80). 
miRNAs are classified into two types based on their genomic location: the intragenic miRNAs 
located within introns or exons of protein coding genes which are considered as the miRNA 
“host” genes, and the intergenic miRNAs located between genes. Intergenic miRNAs are 
generally believed to be transcribed as independent transcriptional units. Microarray profiling 
of 175 human miRNAs across 24 different human organs reveals a similarity in expression 
pattern between intragenic miRNAs and their host genes, suggesting that intragenic miRNAs 
are processed from the same primary transcripts as their host genes (81). In an effort to identify 
promoters of miRNAs, two studies using two different approaches, chromatin structure analysis 
and Pol II chromatin immunoprecipitation analysis, came to the same conclusion that about one 
third of the intragenic miRNAs have their own promoter and are transcribed independently 
from their host genes (82,83). Pri-miRNA transcription is also regulated by transcription factors 
such as c-Myc or p53 (80). For instance, p53 directly binds to the promoter of miR-200c and 
transactivate miR-200c, resulting in EMT inhibition and suppression of the stem-like 
phenotype in mammary carcinoma cells (68). Even though pri-miRNA transcription shares 
some similarities with mRNA transcription, a complete understanding of pri-miRNA 
transcription regulation is still illusive. 
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Figure 3: “The ‘linear’ canonical pathway of microRNA processing. The miRNA 
processing pathway has long been viewed as linear and universal to all mammalian 
miRNAs. This canonical maturation includes the production of the primary miRNA 
transcript (pri-miRNA) by RNA polymerase II or III and cleavage of the pri-miRNA by 
the microprocessor complex Drosha–DGCR8 (Pasha) in the nucleus. The resulting 
precursor hairpin, the pre-miRNA, is exported from the nucleus by Exportin-5–Ran-
GTP. In the cytoplasm, the RNase Dicer in complex with the double-stranded RNA-
binding protein TRBP cleaves the pre-miRNA hairpin to its mature length. The 
functional strand of the mature miRNA is loaded together with Argonaute (Ago2) 
proteins into the RNA-induced silencing complex (RISC), where it guides RISC to 
silence target mRNAs through mRNA cleavage, translational repression or 
deadenylation, whereas the passenger strand (black) is degraded. In this review we 
discuss the many branches, crossroads and detours in miRNA processing that lead to the 
conclusion that many different ways exist to generate a mature miRNA”. Reprinted by 
permission from Macmillan Publishers Ltd: Nat Cell Biol (80), copyright (2009) 
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2.2. Canonical miRNA processing 
MiRNA processing in the nucleus 
Generation of the pre-miRNA: the long pri-miRNAs are cleaved in the nucleus by the 
microprocessor complex, comprised of the RNAse type III Drosha and a double-strand RNA 
binding protein DGCR8 to form a stem-loop-shape double-strand precursor (pre-miR). Pri-
miRNA contains a double-strand hairpin stem of 33 base-pairs, a loop and two single-strand 
flanking regions upstream and downstream of the hairpin. The double-strand stem and the two 
single-strand flanking sequence are crucial for DGCR8 recognition and Drosha cleavage. 
Drosha cleaves the 5‟ and 3‟ arms of the pri-miRNAs at 11 base pairs away from the junction 
between single and double-strand RNA toward the loop (Fig. 3). Pri-miRNAs cleavage 
mediated by Drosha happens co-transcriptionally in both independently transcribed miRNAs 
and intragenic miRNAs whose transcription is host gene-dependent (80,84). 
Nuclear export to the cytoplasm: correctly processed pre-miRNAs are exported into the 
cytoplasm by Exportin-5 (XPO5) associated with Ran-GTP (Fig. 3). Pre-miRNAs nuclear 
export mediated by Exportin-5 is independent of their sequence and mainly depends on the 
length of the double-strand stem and the 3‟ overhangs. As a result, only pre-miRNAs which are 
correctly processed can appropriately bind to Exportin-5 and be exported (80). 
MiRNA processing in the cytoplasm 
Generation of the mature miRNA: In the cytoplasm, pre-miRNAs are processed by the 
RISC loading complex (RLC) to form mature miRNA (Fig. 3). RLC is comprised of the 
RNAse III Dicer, the double-strand Tar RNA-binding protein (TRBP) and protein activator of 
PKR (PACT) and the core catalytic component Argonaute-2 (Ago2) which has endonuclease 
activity. TRBP and PACT may have overlapping functions and even though they both help 
recruiting Ago2, functional RLC and RISC can be achieved by TRBP, Dicer and Ago2 alone 
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(85,86). For the pre-miRNAs whose hairpin stems have a high degree of complimentary, Ago2 
creates a nick in the middle of the 3‟ arm of the hairpin by their endonuclease capacity to 
generate the Ago2-cleaved precursor miRNA (ac-pre-miRNA). The cleaved strand is the 
potential passenger strand and this cleavage is believed to facilitate subsequent dissociation of 
the miRNA duplex (87).  Hairpin pre-miRNAs as well as ac-pre-miRNAs are then subject to 
cleavage by the RNAse III Dicer to remove the loop. The miRNA duplex products contain 
approximately 22 nucleotides with an additional 2 nucleotides overhang at each 3‟ end (80). 
RISC formation: After cleaving out the loop, Dicer and TRBP dissociate from the 
duplex. The miRNA duplex contains a functional single strand (also known as seed strand) that 
is incorporated into RISC and guide RISC to target mRNAs and a passenger strand that is 
degraded (Fig. 3). The dissociation of the functional strand and the passenger strand could be 
mediated by helicases; however, a universal helicase responsible for duplex unwinding is yet to 
be identified. Ago2, on the other hand, can facilitate duplex unwinding and RISC formation by 
cleaving the passenger strand, triggering its dissociation from the complex. Dissociated 
passenger strand is subsequently degraded. Functional strand guides active RISC to target 
mRNAs by complementary base-pairing with the targets. RISC inhibits protein expression by 
many distinct ways that result in translation inhibition, mRNA destabilization or mRNA 
degradation, most of which are mediated by Ago2, the main effector of RISC (80,88) 
2.3. Non-canonical miRNA processing 
miRNA research recently reveals several alternative miRNA biogenesis pathways. The 
most prominent alternative pathway is the biogenesis of intragenic miRNA located within an 
intron (also known as mirtrons) in which Drosha cleavage is substituted by splicing. The 
introns following the mirtron alternative pathway are spliced out and form lariats with the 3‟ 
branchpoint ligated to the 5‟ end of the intron. The spliced lariats are then subjected to 
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debranching by the lariat debranching enzyme (Ldbr) and fold into pre-miRNA hairpins which 
are subsequently exported to the cytoplasm. If the intron are long and the hairpin generating 
sequence locates at one side of the intron, this “tailed” mirtron undergo 5‟-3‟ or 3‟-5‟ trimming 
after being spliced and debranched (89).   
2.4. miRNA degradation 
In contrast to the increasing knowledge about miRNA biogenesis, little is known about 
miRNA degradation. miRNAs are globally stable with much longer half-life than mRNAs. As 
documented in Dicer-ablated mouse embryonic fibroblasts,  miRNA half-lives ranged from 28 
to 220 h, which is about 2- to 20-fold longer than that of mRNAs (about 10h)(90). An 
explanation for the stability of miRNA is the RISC complex which may shield its miRNA 
partner and protect it from cleavage by ribonucleases (91).  Knowledge about factors involved 
in miRNA degradation is still limited. Enzyme involved in miRNA degradation identified so 
far are a family of exoribonucleases encoded by the small RNA degrading nuclease (SDN) 
genes in Arabidopsis, exoribonuclease XRN1/2 in C. elegans, XRN1 and PNPase PNPT1 (also 
known as PNPase) in human (reviewed in (91)). 
 
3. UROTHELIAL DEVELOPMENT AND BLADDER TUMORIGENESIS: THE 
ROLE OF STEM CELLS 
3.1. Introduction about stem cells 
Stem cell is the term assigned for unspecialized cells that can unlimitedly self-renew 
and differentiate to generate specialized cells. Stem cells are classified into the stem cell 
hierarchy based on their differentiation potential as totipotent, pluripotent, multipotent, 
opligopotent, and unipotent (92) (Fig. 4). Cells in the higher rank are more potent and can give 
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rise to cells in the lower rank. Totipotent stem cells are at the top of the stem cell hierarchy. 
These cells can differentiate to any types of cells in the organism. In terms of human 
development, the zygote is the earliest totipotent stem cell which can generate cells in all three 
germ layers (endoderm, mesoderm and ectoderm) in the embryo as well as extraembryonic 
cells (92). Pluripotent stem cells are embryonic stem (ES) cells which reside in the inner cell 
mass of the blastocysts (93). ES cells can differentiate into all three germ cell layers; however, 
they cannot generate extraembryonic cells. ES cells can be maintained and expanded in 
undifferentiated state in vitro, providing a model for basic stem cell study as well as promising 
therapies based on stem cell transplantation (94). A revolution discovery in stem cell study is 
the generation of induced pluripotent stem (iPS) cells from mouse embryonic and adult 
fibroblast by introducing four transcription factors Oct3/4, Klf4, Sox-2, and c-Myc, under ES 
cell culture conditions (95). This study highlights the capacity of differentiated cells to 
dedifferentiate to acquire „stemness‟. 
Right below pluripotent stem cell in the potency hierarchy is multipotent stem cell 
which can generate specific cell types in multilineages. Examples of multipotent stem cells are 
haematopoietic stem cells giving rise to cells in the myeloid lineage (thrombocytes, basophil, 
neutrophil, eosinophil, and macrophage) and cells in the lymphoid lineage (T cells, B cells, and 
Natural Killer cells), and bulge stem cells (in the skin) forming multiple lineages including 
cells in the epidermis, hair follicle, and sebaceous gland (Fig. 4). Multipotent stem cells are 
present in adult tissue; therefore, they are also referred to as adult stem (AS) cells (93). AS cells 
are critical for organ maintenace, tissue regeneration and wound healing. Stem cell niche is the 
crucial determinant of AS cell‟s lineage differentiation program. AS cells of a specific tissue 
can give rise to cell types of that tissue; however, when embedded in a different stem cell 
niche, AS cells can differentiate into the specialized cells of the new environment. For instance, 
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neural stem cells from mouse and human can produce skeletal myotube in vitro (by direct 
exposure to myoblasts) and in vivo (by injection into tibialis anterior), demonstrating that 
neural stem cells, which generate neuron, glia and blood cells, can differentiate to form skeletal 
muscle cells upon exposure to signals from the muscle tissue (96). 
Oligopotent stem cells can produce only a few cell types within a certain lineage. A 
typical opligopotent stem cell is the myeloid precursor cell which differentiates to five types of 
blood cell: monocytes, macrophages, eosinophils, neutrophils, and erythrocytes. Unipotent cells 
only give rise to a single cell type, for example: mast cell progenitors in the bone marrow only 
produce mast cells (97). 
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Figure 4: “Hierarchy of stem cells. (A) Developmental hierarchy. A zygote (fertilized 
egg) can form both embryonic and extra-embryonic tissues and is therefore at the top of 
the hierarchy of stem cells and is termed „totipotent‟. The inner cell mass of the 
blastocyst gives rise to three germ layers: mesoderm, endoderm and ectoderm as well as 
to germ cells. The inner cell mass and the embryonic stem (ES) cells isolated from the 
inner cell mass are therefore termed „pluripotent‟. An adult stem cell is an 
undifferentiated cell that is found among differentiated cells in a tissue, which can 
renew itself and can differentiate to yield some or all of the major specialized cell types 
of the tissue. Adult stem cells are termed „multipotent stem cells‟. (B) Hierarchy of 
adult stem cells. Adult stem cells in many tissues divide only rarely, but give rise to 
daughters that are committed to differentiation, named transit-amplifying (TA) cells, 
which go through a limited series of more rapid divisions before completing the 
differentiation process”. Reprinted from Cancer Lett, 308, Kyo, S. et al., Stem cells in 
endometrium and endometrial cancer: accumulating evidence and unresolved 
questions, 123-133 (2011), with permission from Elsevier 
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3.2. Normal urothelial stem cells 
The normal human bladder wall consists of four layers: the urothelium, lamina propria, 
muscularis mucosae, and periversical soft tissue in sequential order. Urothelium is the 
epithelium lining the urinary tract, forming a barrier to protect the underlining tissues from 
potential harm from urine. Urothelium is classified as transitional epithelium since urothelial 
cells are able to change their shape when the bladder tissue contracts or expands to adapt to the 
urine amount. Urothelium is a stratified epithelium, comprised of 3-6 layers of cells: a single 
basal cell layer attaching on the basement membrane, one or more intermediate cell layer(s) on 
top of the basal layer, and a single superficial cell layer (umbrella cell layer) exposed to the 
lumen (Fig. 9). Basal cells are the smallest cells of the three (10-20µm in width). They are 
cuboidal cells with sharply indented nuclei occupying majority of the cytoplasm (98). 
Intermediate cells are at the intermediate degree of location, size and shape. Similar to basal 
cells, intermediate cells are mononuclear (98). Superficial cells are the largest (ranging from 
20-40µm in width) polygonal cells covering the inner side of the bladder wall, which is the 
reason why they are referred to as „umbrella‟ cells (98). The size and shape of superficial cells 
largely depend on the filling state of the bladder. In unfilled bladder, superficial cells are almost 
cuboidal in shape; whereas in filled bladder, they stretch out to squamous morphology (99). 
The superficial layer directly faces the lumen and plays the critical protective role in the 
urothelium barrier. Superficial cells are connected by tight junctions providing an effective seal 
at the cell-to-cell junction. Superficial cells are mononuclear, or binuclear (98).  
Under normal conditions, the urothelium turnovers every 3-6 months (99). Constant 
exposure to ions, solutes, and water flux, as well as potential toxic and pathogen from the urine 
makes superficial cells the most frequently replaced type of cells in the three. Intermediate cells 
and basal cells are the source of replacement of superficial cells upon pathological damage or 
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chemically induced injury. Monitored exposure to appropriate amount of protamine sulfate 
selectively damaged the superficial layer of rat bladder, resulting in necrosis and sloughing of 
sheets of superficial cells. To replace the damaged superficial cell layer, the underlying 
intermediate cells underwent rapid maturation to become functional superficial cells within 3-5 
days (100). Investigation of the murine urothelium wound healing process upon superficial or 
full-thickness injuries revealed that the basal cells rapidly proliferate and regenerate the 
urothelium within 72hrs (101). These data suggest the presence of urothelial stem cells which 
are activated to regenerate the urothelium upon injury. In addition, the differentiation hierarchy 
of urothelial cells is also indicated with superficial cells being the most differentiated and the 
basal cells - the least differentiated cells. 
The location of urothelial stem cells is a research interest for many years. Basal cells are 
the potential candidate of urothelial stem cells. Due to their importance in maintaining and 
regenerating the organ, stem cells usually locate in a protective environment, such as the 
intestine crypt base where the intestinal stem cells reside. The urothelial basal cell layer, which 
is separated from the lamina propria by the basement membrane and protected from urine by a 
layer of superficial cells and 1-4 layers of intermediate cells, is prominently a well protective 
environment for stem cells. Another feature of stem cells is their slow recycling characteristic. 
Stem cells of cornea (102), prostate (103) and epidermis (104) have been identified by cell 
labeling method to detect slow recycling cells. In label retaining assays, cells are exposed to 
labeled (
3
H-thymidine) or synthetic (5-bromo-2‟-deoxyuridine - BrdU) nucleosides for a 
specific amount of time. Proliferating cells incorporate these nucleosides into their DNA during 
S phase. Normal cells with rapid but limited recycling potential incorporate the label faster, 
mature, die and lose the label, while stem cells with self-renewing and slow-recycling cells 
incorporate the label and retain the label in their DNA for a long time. Thus, label-retaining 
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cells (LRCs) are candidates of stem cells. In one study applying the label retaining (BrdU) 
assay in rat bladder, LRCs were identified at the basal layer of urothelium (105). These cells 
retain BrdU for 1 year and account for about 9% of basal cells. In vitro characterization reveals 
that these cells strongly express β4 integrin and are highly clonogenic (105). Interestingly, 
basal cells can switch from the normal cytostatic state to highly proliferative state and 
regenerate all cell types in the urothelium in response to bacterial infection or chemical injury 
of the mouse bladder (106). In general, these data suggest that urothelial stem cells are basal 
cells (Fig. 5). 
However, this urothelial stem cell hierarchy model starting from basal cells as urothelial 
stem cells, to intermediate cells and finally to superficial cells as specialized cells is challenged 
by studies of p63‟s role in urothelial development. p63 is a homolog of the transcription factor 
p53. p63 is highly expressed in basal/intermediate cells of the urothelium while superficial cells 
are negative for p63. Interestingly, p63
-/-
 mice develop a bladder with abnormal urothelium, 
comprised of only a single layer of cells. These cells express CK18, uroplakin II (107) and 
uroplakin III (108), consistent with a superficial cell phenotype. These data strongly suggest 
that superficial cells can be generated and maintained independent of basal/intermediate cells. 
Moreover, by complementing p63-/- blastocysts with p63+/+ ES cells, Signoretti, S. et al. 
generated a chimeric mouse bladder comprised of both p63
-
 and p63
+
 cells (108). While p63
+
 
cells populated basal and intermediate cells, p63
-
 cells did not (108). Remarkably, p63
+ 
cells 
contributed to only 0-15% of superficial cells (108). This chimeric mouse model emphasizes 
the presence of another pool of urothelial stem cells independent of basal cell origin (Fig. 5). 
 
 
31 
 
 
 
 
 
 
 
Figure 5: Urothelial stem cell hierarchy. Thin black arrows denote the sequential transition 
from one differentiation stage to another starting from the undifferentiated stem cells to the 
highly specialized umbrella cells. Dotted thin black lines demonstrate a hypothetical alternative 
pathway of differentiation. Markers associated with each differentiation stage are noted. Thick 
black arrows denote the increase in levels of expression. Reprinted by permission from 
Macmillan Publishers Ltd: Nat Rev Urol (92), copyright (2012). 
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3.3. ‘Stemness’ in bladder tumorigenesis: cancer stem cells (CSC) 
Tumor heterogeneity is a hallmark of cancer. This term denotes the presence of various 
types of cells within a tumor, generated by random genetic and epigenetic events inside tumor 
cells. Cancer cells can be clustered into different subpopulations within a tumor. This feature of 
cancer is somewhat similar to normal tissues which also consist of different subpopulations of 
cells with different level of differentiation. In the case of the urothelium of the bladder, these 
subpopulations are basal (undifferentiated), intermediate (intermediate-differentiated) and 
superficial (well-differentiated) cells. As a result, the cancer stem cell (CSC) hypothesis was 
built upon our understanding about normal development to explain our pathological 
observation of intratumoral heterogeneity. CSC hypothesis postulates the presence of an 
intratumoral differentiation hierarchy in which a subpopulation of cells (functionally termed 
CSC) possesses stem cell properties including self-renewal and differentiation to generate 
different types of cells within the tumor bulk (70). CSCs can originate from different type of 
cells including normal stem cells with original stemness or transit amplifying/differentiated 
cells acquiring stemness via dedifferentiation during carcinogenesis process (70). Even though 
CSC can initiate tumor formation, the CSC term does not indicate the cancer cell of origin 
which is the cell initiating the original tumor (70). Since CSCs appear to be responsible for 
tumor initiation, tumor maintenance, drug resistance, tumor progression and metastasis, 
multiple research efforts have been focusing on isolating and characterizing CSC in various 
types of cancer including bladder cancer (BC) (92,109).  
Cell surface markers are the main tools to identify and isolate viable CSCs. There are 
multiple markers of CSCs have been published for BC including epithelial membrane antigen 
(EMA), CD44v6, CD44, 67 kDa Laminin receptor (67LR), carcinoembryonic antigen-related 
cell adhesion molecule 6 (CEACAM6) and CD90 (Table 1). The models from which bladder 
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CSCs were isolated vary from cell lines to patient-derived xenografts and primary patient 
tumors. Since majority of cancer cell lines have been isolated out of their tumor 
microenvironment and cultured in plastic for a long time, they are not an ideal model for CSC 
research, provided that microenvironment is crucial for the maintenance of normal as well as 
neoplastic stem cells. Therefore, freshly isolated patient tumors or early in vitro passage tumor 
cells from patients are more reliable for CSC isolation and characterization. The critical 
functional characteristic of CSCs is their tumorigenicity, thus they are also referred to as tumor-
initiating cells. The gold standard method to characterize CSC tumorigenicity is the in vivo 
serial transplatation with limiting dilution. Chan et al. successfully isolated bladder CSCs from 
primary human BC specimens using the cell surface marker CD44 (110). They demonstrated 
that CD44
+
 tumor cells are 10-200 fold more tumorigenic than CD44
-
 tumor cells in the in vivo 
tumor initiation assay using the immunocompromised RAG2
–/γc– mouse model. Moreover, 
tumors formed by these CD44
+
 cells recapitulated the tumor heterogeneity of the original 
tumors. As a result, CD44
+
 cells qualify all the functional criteria of CSCs (110). Another 
research group also reported bladder CSC subpopulation which is positive for CD44v6, a 
spliced variant of CD44, and negative for EMA (111). In an effort to isolate highly tumorigenic 
BC cells, He et al. established that 67LR
+
 and CEACAM6
-
 cells are more efficient in xenograft 
formation than their opposite counterpart (i.e. 67LR
-
; CEACAM6
+
 cells) (112). Interestingly, 
all of the cell surface markers used to isolate bladder CSC (CD44
+
, CD44v6
+
, 67LR
+
, 
CEACAM6
-
) are also markers of basal cells in normal urothelium (Fig. 5) (111,112), indicating 
the basal cell characteristics of bladder CSCs.  
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Study Study design CSC markers Tumor cell type 
Tumorgenic 
potential 
Yang & Chang 
(111) 
In vitro colony-
forming assay  
EMA
–
; CD44v6
+
 Primary patient None reported 
She et al.(113) 
In vitro colony-
forming assay  
SP (DyeCycle 
violet staining) 
SW780 >10 fold 
Ning et al.(114) 
In vitro colony-
forming assay  
SP (Hoechst 
33342) 
T24 6-fold 
He et al.(112) 
In vivo colony-
forming assay 
and athymic 
nude mouse 
model assay 
67LR
+
; 
CEACAM6
–
; 
CK17
+
 
SW780 and 
primary patient 
(once-passaged)  
5-10 fold 
Chan et al.(110) 
In vivo colony-
forming assay 
and in vitro 
RAG2
–/γc– 
mouse model 
assay 
CD44
+
; CK5
+
; 
CK20
–
 
Primary patient 
and patient-
derived 
xenografts 
10–200-fold 
Su et al.(115) 
In vivo colony-
forming assay 
and athymic 
Swiss nude 
mouse model 
assay 
ALDH1A1 
 
HTB-2; HTB-9; 
HTB-4 
 
100 fold 
Volkmer et al. 
(116) 
In vivo RAG2
–
/γc– mouse 
model assay 
CD90
+
/CK14
+
 
 
Primary patient 
and patient-
derived 
xenografts 
17-fold 
 
“Abbreviations: 67LR, 67 kDa laminin receptor; ALDH1A1, aldehyde dehydrogenase 1 
family, member A1 (retinal dehydrogenase 1); CD, cluster of differentiation; CEACAM6, 
carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting 
antigen); CK, cytokeratin; CSC, cancer stem cell; EMA, epithelial membrane antigen; HTB, 
human tumour cell bank; γc, common cytokine receptor gamma chain; RAG2, recombination 
activating gene 2; SP, side-population.“ 
Table 1: Selected studies of urothelial CSC marker. Reprinted by permission from 
Macmillan Publishers Ltd: Nat Rev Urol (92), copyright (2012). 
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Cytokeratins are keratin-containing intermediate filaments localized in the 
intracytoplasmic cytoskeleton of epithelial tissues (including urothelium). The complex 
network formed by cytokeratin extends from the surface of the nucleus to the plasma 
membrane, provide the tensile strength to the cells and support the nucleus. Cytokeratins are 
differentially expressed during differentiation. Different cytokeratins are associated with 
different type of cells in the urothelium and used as markers for these cells. CK5/14/17 are 
strongly expressed in basal and/or intermediate cells whereas CK18/20 are expressed in 
intermediate and/or superficial cells (Fig. 5 and Fig. 9). Due to their intracellular location, 
cytokeratins are not appropriate to use as marker for the isolation of viable tumor cells by 
Fluorescent activated cell sorting (FACS). However, they are very informative tools to study 
the differentiation status of tumor cells. Interestingly, Chan et al. discovered that their bladder 
CD44
+
 CSCs co-expressed CK5, the basal cell markers, while the CD44
-
 non-CSCs co-
expressed CK20, the superficial cell marker. In addition, the CD44
+
 cells were relatively small, 
with a high nuclear: cytoplasmic ratio, a well-established phenotype of basal cells. CD44
-
 cells, 
on the other hand, were heterogenously moderate or large in size, similar to the phenotype of 
normal differentiated urothelial cells (110). Therefore, this group of researchers categorized BC 
into three subpopulations based on normal differentiation markers: basal (CK14
+
CK5
+
CK20
-
), 
intermediate (CK14
-
CK5
+
CK20
-
) and differentiated (CK14
-
CK5
-
CK20
-
). Analyzing these three 
BC subopulations using a computational algorithm known as mining developmentally regulated 
genes (MiDReG) revealed two other cell surface markers Thy-1(CD90) and ITGA6 (CD49f) 
that were up-regulated in the basal BC subpopulation and down-regulated in the differentiated 
BC subpopulation. The combination of the three cell surface markers CD44/90/49f classified 
BC cells into four subsets with predicted developmental lineage. Interestingly, 
xenotransplatation using subfractionated BC cells from FACS with CD44/90/49f markers in the 
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basal, intermediate, differentiated subpopulations showed that only the most upstream 
population could regenerate tumors and recapitulate all downstream population (117). An 
independent study by He et al. demonstrated that 67LR+ CSC located at the tumor-stroma 
interface and strongly expressed the basal cell marker CK17 while non-CSC located inside the 
tumor nest expressed the superficial cell marker CK20 (112). Collectively, this evidence, again, 
highlight the basal cell traits in bladder CSCs, indicating that bladder CSCs can either originate 
from normal basal cells or from dedifferentiated intermediate/superficial cells. In addition, they 
demonstrate the presence of differentiation hierarchy in BC and the correlation between this 
hierarchy with tumorigenesis. More importantly, these data suggest that the basal cell 
phenotype/markers can be used to identify subpopulation of bladder CSCs or used as 
prognostic markers in patients providing that CSCs is the „roots‟ of cancer progression and 
lethality.   
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4. BLADDER CANCER 
4.1. Incidence and classification of bladder cancer and treatment 
Bladder cancer (BC) was ranked as the fourth leading type for estimated new cancer cases and 
the eighth leading type for estimated deaths in males in the United States in 2012 (118). The 
majority of BCs (90%) are carcinoma of the urothelium (urothelial carcinoma – UC), formerly 
called transitional cell carcinoma (TCC). The urothelium is the stratified transitional epithelium 
lining the urinary tract (National Cancer Institute, 2012). The TNM classification system is 
applied for pathologic staging of BC (Fig. 6). The depth of tumor penetration into the tissue of 
the bladder (T), the regional lymph node status (N) and the presence or absence of distant 
metastases (M) reflect the severity of BC in specific patients. Tumor grade reflects the 
microscopic histological abnormality of tumor cells, which is also very helpful for oncologists 
to determine treatment regimens. Bladder cancer is divided into two major phenotypic variants: 
80% of the cases are low-grade papillary non-invasive tumors (termed “superficial tumors”) 
and the rest 20% are high-grade invasive tumors (termed “muscle invasive tumors”) (119). 
Superficial tumors arise from hyperplastic urothelium. These tumors (stage Ta and T1) tend to 
localize within the bladder and rarely invade into the muscle, therefore, rarely metastasize. 
However, their frequent recurrence after resection makes BC the most costly malignancy to 
healthcare systems due to the requirement of intensive surveillance and frequent tumor 
resections (120,121). Muscle invasive bladder cancer (MIBC) arises from severe dysplasia or 
carcinoma in situ (CIS). The majority of MIBC patients do not have prior history of superficial 
tumors. Muscle invasive tumors tend to invade into the muscle and metastasize to regional 
lymph nodes and distant organs. As a result MIBC is lethal and very challenging in terms of 
treatment. Despite multi-modal therapy including radical surgery and systemic chemotherapy, 
50% of MIBC patients succumb to the disease. About 10-15% of superficial tumors progress to 
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muscle invasive tumors, preceded by CIS in the adjacent bladder mucosa or within the 
papillary tumor (122). To identify an effective therapy for MIBC as well as a recurrence 
prevention therapy for superficial tumor, the molecular biology underlying aggressiveness of 
MIBC cells, the recurrence tendency of superficial tumor and the progression from superficial 
to muscle invasive phenotype needs to be explored. 
 
Figure 6: Bladder cancer stage. CIS (carcinoma in situ): small lesion in the innermost layer of 
the urothelium, high grade. Ta: tumors are restricted in the urothelium. T1: tumors have started 
to grow into the lamina propria, the connective tissue underneath the urothelium. T2: tumors 
have invaded into the muscle underneath the lamina propria. T3: tumors have invaded through 
the muscle into the fat layer. T4: the cancer has grown through the bladder wall and spread 
outside the bladder. Taken from CancerHelp UK, the patient information website of Cancer 
Research UK: http://www.cancerresearchuk.org/cancerhelp  
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4.2. Molecular pathways of BC progression 
The dual-tract concept generalizes bladder carcinogenesis in two distinct but somewhat 
overlapping pathways: the papillary pathway accounting for superficial BC and the non-
papillary pathway accounting for MIBC (Fig. 7) (119,122). These two pathways overlap at the 
initial step, when normal urothelium acquire genetic alterations leading to the formation of 
hyperplasia (also referred to as low-grade intraepithelial neoplasia – LGIN) with strong 
proliferation capacity determined by expression of Ki67 in the entire LGIN and the 
upregulation of the tumor suppressor RB also in the entire LGIN. These genetic alterations are 
loss of heterozygosity (LOH) and/or mutation at regions containing loci of critical genes such 
as p16/ARF and IFNα (9p region), and TSC1 (9q.34). Six critical regions (3q22, 5q22–23, 
9q21, 10q26, 13q14, and 17p13) were identified as drivers of human BC development (122). 
Mutation and/or single nucleotide polymorphism (SNP) at regions surrounding Rb gene 
resulting in inactivation of genes located in these regions is determined as a risk factor of BC 
development. These genes are referred to as “forerunner genes” since their inactivation 
precedes inactivation of RB, a well-established critical tumor suppressor in BC (122). Aromatic 
amines or nitrosamines from tobacco smoke or industrial solvent are determined as a 
carcinogen for BC (123). Similar to its effect on other types of cancer, tobacco causes DNA 
alterations throughout the entire bladder, initiating bladder carcinogenesis process (122). 
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Figure 7: “Dual-track concept of bladder carcinogenesis. The expansion of a preneoplastic 
clone, which shows minimal phenotypic deviation from the normal urothelium, is the incipient 
event in bladder carcinogenesis referred to as LGIN. In this phase, the loss of FR genes 
function provides growth advantage associated with the expansion of proliferating 
compartment. The proliferating cells expressing normal RB protein are seen in the entire 
thickness of LGIN. In contrast, normal urothelium contains only scattered proliferating cells 
expressing RB protein located in its basal layer. The continuous growth of LGIN leads to the 
development of low grade superficial papillary TCC. In the non-papillary pathway, clonal 
evolution results in the establishment of a successor clone with microscopic features of HGIN, 
which often shows a loss of major tumor suppressors such as RB1 and has a high propensity for 
progression to an invasive high grade non papillary TCC. (A) Normal urothelium (upper 
panel). Expression of Ki67 in proliferating basal cells of normal urothelium (lower panel, left). 
Expression of RB protein in peribasal cells of normal urothelium (lower panel, right). (B) 
Urothelial hyperplasia with mild atypia referred to as LGIN (upper panel). Expression of Ki67 
in the entire thickness of LGIN (lower panel, left); expression of RB protein in the entire 
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thickness of LGIN (lower panel, right). (C) Low-grade superficial TCC retaining normal 
expression of the RB protein: insets to (C) show low and high power photomicrographs 
illustrating the expression of normal RB protein in low grade papillary TCC. (D) Severe 
intraurothelial dysplasia/carcinoma in situ (HGIN) (upper panel). Loss of RB protein 
expression in HGIN (lower panel). (E) High-grade invasive nonpapillary carcinoma (upper 
panel). Loss of RB protein expression in high grade invasive nonpapillary TCC. Arrow shows 
expression of RB protein in endothelial cells adjacent to tumor, which serve as an internal 
positive control (lower panel). (F) Severe intraurothelial dysplasia/carcinoma in situ developing 
in bladder mucosa adjacent to a low-grade papillary tumor. It is responsible for switching the 
pathway and progression of some low-grade papillary tumors to high-grade invasive cancers”. 
Reprinted from Urol Oncol 28, McConkey, D. J., et al., Molecular genetics of bladder cancer: 
Emerging mechanisms of tumor initiation and progression, 429-440 (2010) with permission 
from Elsevier  
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Studies using transgenic mouse models provide insights into the molecular mechanisms 
of the papillary pathway and non-papillary pathway. By using uroplakin II (UPII) promoter, 
Zhang et al. successfully generated two lines of transgenic mice closely recapitulating the two 
distinct types of BC in human (124,125). UPII is a member of the Uroplakins family (Ia, Ib, II, 
III) which are major protein components of the asymmetric unit membrane (AUM), a hallmark 
of urothelial differentiation (126). UPII is specifically expressed in urothelium, restricted to the 
umbrella cells in normal urothelium (127). Transgenic mice carrying a constitutively active Ha-
Ras oncogene under the control of UPII promoter developed simple urothelial hyperplasia 
followed by superficial papillary tumors (125). In addition, mice bearing a high copy number of 
the Ha-ras transgene displayed urothelial hyperplasia and progressed to papillary tumors at 
much earlier age than mice carrying low copy number of the transgene, strongly suggesting that 
activation of Ha-ras induces the papillary pathway in vivo, and that urothelial hyperplasia is the 
precursor of superficial papillary tumors (125).  
While superficial tumors retain RB expression, loss of RB and p53 is associated with 
MIBC. Intriguingly, when SV40T transgene under the control of UPII promoter was used to 
generate transgenic mice, mice carrying low copy number of the transgene developed only 
bladder carcinoma in situ (CIS), whereas those carrying high copy number of the transgene 
developed CIS as well as invasive and metastatic tumors (124). Since SV40T (SV40 large T 
antigen) inactivates p53 and RB tumor suppressors, the formation of CIS and muscle 
invasive/metastatic tumors (not the superficial tumors) in SV40T transgenic mice demonstrates 
that p53 and RB are responsible for the aggressive muscle-invasive type of BC. The presence 
of only CIS in mice sacrificed at early age and the presence of both CIS and muscle invasive 
lesions in the same bladder of mice sacrificed at older age, suggesting that CIS precedes muscle 
invasive tumors, at least in mice bearing high copy number of SV40T transgene (124). Analysis 
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of mice carrying low copy number of SV40T reveals that p53 was completely loss in CIS of the 
mouse bladder but these CIS persist for a long period of time without muscle invasion and 
eventually develop into high-grade papillary superficial tumors (128). Moreover, the 
combination of p53 inactivation and active Ha-Ras in the bladder of transgenic mice generated 
both low-grade and high-grade papillary tumors but did not promote muscle-invasive tumors. 
These data emphasize the role of p53 in bladder carcinogenesis; however, these data also 
suggest that the formation of MIBC requires inactivation of p53 and additional events such as 
RB inactivation. Another evidence supporting this possibility comes from another transgenic 
mice study that successfully generate muscle invasive tumors by eliminating both p53 and 
PTEN in the bladder urothelium while deletion of p53 or PTEN only does not have any effect 
on the bladder of this mouse model (129). Consistent with this result, PTEN disruption and 
AKT activation are associated with MIBC in patients (129). This study also reports the 
activation of mTOR, a component of the PTEN/PI3K/AKT/mTOR pathway, in mouse and 
human cancer cells, suggesting that mTOR can be a potential therapeutic target for MIBC 
(129). Inactivation of PTEN in the urogenital system of wild-type p53 background mice 
induces the formation of prostate cancer but not bladder cancer (130). As a result, abrogation of 
the p53 pathway is prerequisite for PTEN-dependent bladder carcinogenesis.  
These mouse models successfully recapitulate superficial and MIBC in patients. 
Activating mutations of Ha-ras are common features of BC in which the frequency of Ha-ras 
mutation is associated with grade (131). However, two other studies exploiting urothelial 
carcinoma cell lines and primary bladder tumors fail to associate mutations in Ras family 
members (Ha-ras, K-ras, N-ras) with BC (132,133). The discrepancy regarding Ha-ras mutation 
in BC indicates that Ha-ras mutation varies significantly in different patient populations and 
Ha-ras mutation is not a reliable marker for BC. Interestingly, consistent with the Ha-ras 
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transgenic mouse model result, Ha-ras pathway is activated in superficial tumor via autocrine 
growth factor receptor activation. Fibroblast growth factor receptor 3 (FGFR3) is one of the 
growth factor receptors that harbor activating mutation associated with superficial tumors but 
not MIBC (134,135). Loss of p53 is prerequisite for CIS and combination of p53 and RB loss 
induces MIBC in preclinical mouse models. Similarly, inactivating mutations of p53, 
inactivation of the p53 pathway (loss of p21), and/or alteration of RB were associated with 
increased risk of recurrence and poor survival in both organ-confined and MIBC (136,137). 
Disruption of the RB pathway presenting in patient tumors as loss of RB, inactivation mutation 
of RB or inactivation of p16, an upstream regulator of RB correlates with tumor progression 
(138,139). Finally, LOH within PTEN locus in chromosome 10 leading to loss of PTEN is 
much more commonly detected in MIBC than superficial tumors (140,141). 
The strong homology between p63, a member of the p53 family, and p53 as well as the 
crucial role of p63 in bladder development makes it become an interesting target for BC 
research. Many studies focus on p63 as a biomarker to predict tumor progression. High p63 
expression is well correlated with superficial tumors whereas loss of p63 expression, especially 
Np63, is associated with the aggressive muscle invasive phenotype (142-144). However, high 
Np63 expression in primary muscle invasive tumors correlates with adverse clinical outcome 
(145,146), suggesting a complicated role of p63 in bladder cancer formation and progression. 
Deeper understanding of ∆Np63‟s functions should elucidate the biology of the most lethal 
subset of MIBC 
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5. P63 
5.1. General introduction 
p53, the well-known tumor suppressor protein, has been the subject of intensive 
research for more than three decades. Throughout the last decade, p63, a homolog of p53, has 
become a research interest of scientists in the fields of developmental biology and cancer 
biology. p63 exhibits remarkable sequence and structural homology to p53, especially in the 
DNA binding domain, suggesting overlaps in target recognition specificity. Indeed, p63 can 
bind to p53 response elements (p53REs) in vitro and in vivo (147). p53 targets that are also 
regulated by p63 include but are not limited to p21
Waf2/Cip1
, 14-3-3σ, MDM2, Bax, PERP, 
NOXA (reviewed in (147)). However, p63 and/or p73, another member of p53 family, also can 
regulate transcription of genes p53 does not regulate, among which are genes involved in DNA 
repair such as Rad51, BRCA2, mre11 and Rad50 (148). The transcriptional targets of p53, p63 
and p73 identified by microarray analysis in cells following DNA damage demonstrated that 
p53 family members can cooperate or act independently in transcriptional regulation (148). A 
large number of p63 target genes (almost 1000) were identified by chromatin 
immunoprecipitation (ChIP) on chip analysis, suggesting that p63 plays a key role in a broad 
transcription regulatory network involved in many biological processes (149). 
While TP53 only has a single promoter, the TP63 gene possesses two promoters that 
produce two groups of isoforms – the full length TAp63 group containing full-length 
transactivation (TA) domains and the Np63 group that contain truncated N-terminal domains 
(Fig. 8). Alternative splicing at the C termini of both groups generates three different isoforms, 
named , ,  (Fig. 1) (147,150). Only the  isoforms of p63 have the sterile alpha motif 
(SAM) domain, which is absent in p53. The SAM domain is responsible for protein-protein 
46 
 
interactions in developmental and other processes such as transcriptional activation, chromatin 
remodeling, and focal adhesion (reviewed in (147)). The TAp63 subfamily, with TA domains 
similar to the TA domain of p53, can activate multiple p53 target genes. Np63, which lacks 
the TA domain, was originally believed to act as a dominant negative molecule toward TAp63 
(150). However, the Np63 isoforms are still able to transactivate p53 targets due to a second 
transactivation domain located in their N-termini (151,152). Six p63 isoforms with overlapping 
and independent targets cooperate/antagonize and independently regulate transcription, creating 
the complexity of the p63 transcriptional network (148,153). As a result, mechanistic 
interpretation of the biological effect of p63 family is impossible without knowledge of 
individual p63 isoforms. 
5.2. p63 in development 
p63 first attracted research interest for its crucial role in epithelial development. Two 
different groups produced the first p63-deficient mice, but the different targeting constructs 
they used produced slightly different effects on p63 expression that had important 
consequences for the phenotypes that resulted from them.  Even though the developmental 
abnormalities were identical in p63 knockout mice generated by two independent groups of 
scientists, the groups‟ interpretations regarding the role of p63 in embryonic development were 
distinct. While p53 knockout mice survive and develop normally but are prone to cancer (154), 
p63 knockout mice lacking all p63 isoforms die one day after birth and have severe defects in 
limb, craniofacial and epithelial development. Developmentally abnormal epithelial tissues in 
p63 null mice include the skin, prostate, mammary gland and urothelium (155,156). Since the 
p63 null mice generated by Mill et al have an unstratified single cell layer epithelium that 
covers the body surface, tongue, and oral cavity where differentiation markers are absent, they 
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concluded that p63 is essential for lineage commitment and differentiation (155). However, 
Yang et al. observed clumps of differentiated cells in the epidermis, suggesting that p63 is 
crucial for maintaining the stem/progenitor cell population in the epithelium (156). Subsequent 
reconstitution studies shed light on the specific roles of p63 isoforms in development. 
Transgenic mice expressing either ∆Np63α or TAp63α under the control of K5 promoter were 
bred onto a p63 null background to generate mice expressing ∆Np63α and/or TAp63α in the 
epidermis. Only p63
-/-
;∆Np63α mice significantly developed an epidermal basal layer, whereas 
the p63
-/-
;TAp63α‟s phenotype was similar to the p63 null mice. Co-expression of ∆Np63α and 
TAp63α rescued the epidermis, further, resulting in the formation of larger patches of 
differentiated skin. These data demonstrate that ∆Np63α is crucial for retaining the 
precursor/progenitor cell population in the basal layer whereas TAp63α acts synergistically or 
subsequently to control epithelial development. Consistently, ∆Np63α regulates expression of 
basal epidermal genes such as K14; whereas TAp63α controls expression of differentiation 
markers within the upper layer of the skin such as Ets1, K1, transglutaminases, and involucrin 
(157). During development, ∆Np63 isoforms are expressed shortly after gastrulation and 
remain restricted to the basal layer of the epidermis, since the epidermis at this stage (prior to 
the epidermal stratification) is only a single layer of ectodermal cells. On the other hand, 
TAp63 isoforms are only weakly expressed, and only in suprabasal cells (158). A recent study 
investigating ∆Np63-null mice further illustrates the critical role of ∆Np63 in epithelial 
development and differentiation (159). ∆Np63-null mice die shortly after birth and exhibit a 
developmental defective phenotype strongly similar to the phenotype of p63-null mice in which 
all of p63 isoforms are deleted (159). Interestingly, keratinocytes from ∆Np63-null mice 
formed a basal cell layer and patches of them stratified and committed to differentiation, which 
appeared to be unbalanced and accelerated, because it was associated with the premature 
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expression of terminal differentiation markers (159). These data highlight the indispensable 
role of the ∆Np63 isoforms in epithelial development, specifically in proliferation of basal 
keratinocytes in embryonic epidermis and proper differentiation (159). Unlike ∆Np63-null 
mice, TAp63
-/-
 mice survived after birth and had median lifespans of 333 days (160). However, 
TAp63
-/-
 mice exhibited multiple signs of premature aging and developed blisters, ulcerated 
wounds in the skin, and senescence of hair follicle-associated dermal and epidermal cells, 
potentially due to the crucial role of TAp63 in the maintenance of dermal and epidermal 
precursors (160). Analysis of TAp63
-/-
 mice revealed that TAp63 participates in maintaining 
adult skin stem cells by regulating cellular senescence and genomic stability (160). Studies 
from the ∆Np63-/- and the TAp63-/- mouse models suggest that the ∆Np63 isoforms are 
important in maintaining the proliferation capacity of basal keratinocytes in embryogenesis 
whereas the TAp63 isoforms regulates proliferation of epidermal and dermal precursor cells 
post embryogenesis. These studies also emphasize the essential of both ∆N- and TA- isoforms 
in regulating proper differentiation of skin stem cells.   
Similar to other stratified epithelia, bladder urothelium development is severely 
impaired in p63 null mice. In normal urothelium, cells in the basal and intermediate layers 
express p63 while the terminally differentiated umbrella cells do not (146). The bladders of p63 
null mice have the phenotype of bladder extrophy, characterized by loss of the abdominal and 
ventral bladder wall. The ventral bladder of p63
-/-
 mice is covered with a thin membrane 
comprised of a single layer of cells positive for K18 (also known as CK18), a marker of 
intermediate (transit amplifying) and terminally differentiated umbrella cells, and negative for 
Uroplakin III (UPIII), which is also a marker of umbrella cells. During bladder development in 
p63
+/+
 mice, whereas the TAp63 isoform is only transiently expressed, ∆Np63 isoforms 
(∆Np63β, ∆Np63γ) are the predominant isoforms expressed, especially at the ventral bladder 
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area where they function as anti-apoptotic factors to maintain the stem cell population by, 
potentially, suppressing the expression of the apoptotic mediators Bax and Apaf1(161). In 
contrast, in a recent publication, Karni-Schmidt et al. reported that the urothelium in p63-null 
embryos contains a single layer of cells positive for both CK18 and UPII, which are markers of 
umbrella cells, the most differentiated cells in urothelium. By using newly generated ∆Np63, 
p63α, and p63α/β antibodies, as well as commercially available p63 antibodies, they 
demonstrated that TAp63α is the first isoform detected in p63+/+ urothelium, as early as E16.5, 
whereas the ∆Np63 isoform is only detected after birth (146). The discrepancies in the results 
from these two groups are potentially due to the use of different p63 antibodies, and further 
efforts are required to conclusively resolve the issue.  
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Figure 8: Schematic illustration of TP63 gene and its six protein isoforms. TP63 gene has 
two promoters (P1 and P2) resulting in two groups of isoforms one with the transactivation 
domain (TAp63) and without the TA domain at the N-terminus (∆Np63). Alternative splicing 
at the C-terminus generates the α, β, γ isoforms in each group. The DNA-binding domains of 
p63 isoforms are strongly homologous to DNA-binding domain of p53. SAM, sterile alpha 
motif; TA, transactivating isoform; TP, tumor protein. Republished with permission of Annual 
review of pathology, from “p63 in epithelial survival, germ cell surveillance, and neoplasia”, 
Crum C. et al., 5, 2010; permission conveyed through C opyright C learance C enter, Inc.  
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5.3. p63 in normal tissues and tumors 
In normal tissue, p63 is highly expressed in the basal and suprabasal cells of stratified 
and glandular epithelia including the epithelium of foreskin, tonsil, breast, cervix, vaginal 
epithelium, esophagus, prostate, and urothelium. p63 expression decreases with differentiation, 
and terminally differentiated cells are negative for p63 (150,162,163). The p63 4A4 antibody 
that detects all p63 isoforms is the most widely used antibody to examine p63 protein 
expression in tissues. This antibody confirms the presence of p63 in the basal and intermediate 
cell layers and the absence of p63 in the umbrella cell layer in urothelium (143,146) (Fig. 9). 
Since p63 isoforms may function differently, recent research has focused on specific p63 
isoform expression. RT-PCR using p63 isoform specific primers is a sensitive and specific 
method for p63 isoform detection. Antibodies specific for TAp63, ∆Np63, p63α, p63α/β are 
commercially available, however, the sensitivity and specificity of these antibodies are still 
controversial. For example, ∆Np63 is the predominant isoform detected in basal and 
intermediate cells of normal human urothelium by both RT-PCR and immunoblotting (143). 
On the contrary, Karni-Schmidt et al. reported that ∆Np63 protein expression is undetectable in 
normal human urothelium even though they confirmed the presence of ∆Np63 protein in 
normal mouse urothelium (146).  
Unlike p53 whose tumor suppressive functions in cancer are well established, whether 
p63 is an oncogene or a tumor suppressor has been a topic of controversy (164). p63
-/-
 mice 
display severe developmental defects and die shortly after birth; therefore, it is impossible to 
study the effect of germline p63 deficiency on tumorgenesis (155,156). Two independent 
studies of p63+/- mice provide opposite results, one suggests that p63 is a tumor suppressor 
(165), and the other indicates that p63 is not a tumor suppressor and that reducing p63 content 
may even protect cells from tumorgenesis (166). The p63
+/-
 mice from the study of Flores et al. 
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developed tumors starting at 12 months of age. The tumor spectrum of p63
+/-
 mice (histiocytic 
sarcoma, squamous cell carcinoma, lung adenoma) was different from that of p53
+/-
 mice 
(thymic lyphoma, histiocytic sarcoma, rhabdomyosarcoma, osteosarcoma, hemangiosarcoma). 
Interestingly, the wild type p63 allele was lost in tumors from p63
+/-
 mice as the result of loss 
of heterozygosity (LOH). Mice heterozygous for both p53 and p63 (p53
+/-
;p63
+/-
) demonstrated 
a more aggressive tumor type with increased tumor burden and metastatic disease compared to 
the p53
+/-
 and p63
+/-
 mice. Their data strongly support an important role for p63 in suppressing 
tumor initiation, progression and metastasis (165). One year after the publication from Flores et 
al., Keyes et al. reported a completely different result using the same approach. Only 13% of 
their p63
+/-
 mice developed tumors compared to 38% of p63
+/+
 mice that developed tumors at 
28 months of age, suggesting that the p63
+/-
 mice are not tumor prone. Combination of 
heterozygosity in p63 and p53 (p53
+/-
;p63
+/-
) significantly reduced the rate of tumor incidence 
observed in the p53
+/-
 mice. Moreover, expression of both TAp63 and ∆Np63 isoforms was 
maintained in tumors from p63
+/-
 mice (166). The discrepancy between the two studies appears 
to result from the fact that the p63
+/-
 mice used in the two studies were heterozygous for distinct 
p63 alleles (155,156). In addition, it has been reported that the null allele in the p63
+/-
 mice 
from Keyes et al. might still produce some isoforms of p63 (167)(reviewed in (168)). This 
complicates the interpretation of the phenotypes of p53
+/-
;p63
+/-
 and p63
+/-
 mice generated from 
this group since the remaining p63 isoforms may exert tumor resistance effects (168).  
Studies in human malignancies also reveal differences between p53 and p63. While p53 
is frequently mutated and mainly functions as a tumor suppressor, p63 remains intact in many 
cancer types and the role of p63 is tumor type-specific (169). For example, Np63 is highly 
expressed in squamous cell carcinoma of esophagus, and overexpression of p63 induces 
tumorgenesis in non-small cell lung cancer; however, loss of p63 has been associated with 
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tumor progression and poor prognosis in bladder cancer (164). The lack of antibodies that are 
sensitive and specific for detection of p63 isoforms brings difficulties and controversies to p63 
studies in human tumors. Recent discoveries in the p63 field suggest that TAp63 functions as a 
tumor suppressor and ∆Np63 functions as an oncogene (170). In 2010, Su et al. reported that 
TAp63
+/-
 and TAp63
-/-
 mice developed metastatic tumors (171). Combination of TAp63 and 
p53 mutation remarkably enhanced metastatic tumors in mice. TAp63
+/-
;p53
+/-
 and TAp63
-/-
;p53
+/-
 mice developed more metastatic carcinomas and sarcomas than p53
+/-
 mice. Similar 
results were observed when TAp63
+/-
;p53
-/-
 and TAp63
-/-
;p53
-/-
 mice were compared to p53
-/-
 
mice. This group also determined that TAp63 suppresses metastasis by directly activating 
transcription of Dicer and miR-130b (171). Another study from Guo et al. using a TAp63-
specific conditional mouse model demonstrated the crucial role of TAp63 in inducing 
senescence and inhibiting tumorigenesis via a p53-independent pathway (172). ∆Np63, on the 
other hand, is the predominant isoform and is overexpressed in squamous cell carcinomas of 
the lung and head and neck, potentially functioning by inactivating p53 (173-175). Without a 
full-length transactivation (TA) domain at its N-terminus, ∆Np63 can act as a dominant 
negative to p53, TAp63 and TAp73 to inhibit transcription and apoptosis (150,176,177). 
∆Np63α has been shown to suppress p73-dependent apoptosis, promote proliferation, and 
facilitate tumorigenesis (178-180).  
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Figure 9. “Morphologic and immunohistochemical characterization of human 
normal urothelium. (A) Hematoxylin and eosin staining of normal human urothelium; 
(B) CK7 expression, as revealed by immunohistochemistry (IHC), is observed in all 
urothelial layers; (C)–(F) immunophenotypic characterization of urothelial cells by 
expression patterns of cytokeratins and p63: Basal/intermediate cells are characterized 
by the expression of high molecular weight cytokeratin (C) and a p63-positive 
phenotype (E), (F), while CK18 is expressed only by “umbrella” cells (D), (F); All 
microphotographs were taken at 400_ magnification.” “Reprinted from Urol Oncol 28, 
Molecular pathways of urothelial development and bladder tumorigenesis, 401-
408(2010) with permission from Elsevier  
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6. RATIONALE OF THE STUDY 
Cancer statistics highlight the lethality as well as the prevalence of bladder cancer in the 
United States in 2013 (181). Understanding the biology of bladder cancer progression and 
metastasis as well as identifying critical markers of survival is very important for the long term 
purpose of discovering a cure for this disease. Given the crucial role of p63 in maintaining 
stemness during epithelial development, we undertook the present study to explore the role of 
p63 in bladder cancer. Bladder cancer is a very intriguing case in p63 research. Loss of p63 
protein expression, especially the ∆Np63α isoform, has been implicated in tumor progression in 
patients. A majority of low-grade papillary non-invasive tumors express high p63 levels 
whereas a subset of high-grade muscle invasive tumors expresses low p63 levels (144,182). It 
has also been reported that EMT is involved in stemness, tumor progression and metastasis in 
multiple types of cancer, yet p63 expression correlated inversely with EMT markers (ZEB1, 
ZEB2) in human bladder cancer cell lines. We were therefore also interested in studying the 
relationship between p63 and EMT in bladder cancer. 
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CHAPTER 2: 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
57 
 
1. Cell culture 
SW780, RT4, T24, J82, Scaber, TCCSUP, 5637, 1A6, 253J-P and UM-UC3 were 
purchased from American Type Culture Collection (ATCC) (Manassas, VA). BV was 
generated by recycling 253J-P cell line five times in the orthotopic mouse model (183). All 
other cell lines in the UM-UC series are provided by Dr. H. Barton Grossman (Department of 
Urology, MD Anderson Cancer Center). The identities of cell lines were confirmed by DNA 
fingerprinting using AmpFlSTR® Identifiler® Amplification (Applied Biosystems/Life 
Techonologies, Grand Island, NY) or AmpFlSTR® Profiler® PCR Amplification (Applied 
Biosystems/Life Techonologies) in the MD Anderson Characterized Cell Line Core facility or 
by ourselves, respectively. In this study, UM-UC cells are referred to as UC cells. All the cell 
lines were cultured in Minimum Essential Medium Eagle (MEM) (Life Technologies, Grand 
Island, NY) supplemented with 10% fetal bovine serum (FBS) and 1% each of MEM vitamin 
solution (Life Technologies), sodium pyruvate, L-glutamine (BioWhitaker/Fisher Scientific, 
Pittsburgh, PA), L-glutamine, penicillin/streptomycin solution and nonessential amino acids 
(Life Technologies). Cultured cells were kept at 37
0
C in a standard 5% CO2 incubator.  
 
2. RNA isolation and Real-time Reverse Transcription PCR (qRT-PCR) analysis 
The mirVana™ miRNA Isolation Kit (Ambion/Life Techonologies) was used to isolate 
RNA from samples. This kit combines the advantages of two traditional methods of RNA 
extraction - chemical extraction and solid-phase extraction - to provide high yields of pure 
RNA and prevents loss of small RNAs such as microRNA during the extraction procedure. 
Chemical extraction method uses chaotropic salts in combination with acid phenol-chloroform 
solution to inactivate RNAse and separate RNA from other biomolecules. This method can 
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provide pure RNA but usually results in low yield of RNA due to the loss during extraction 
steps, especially the loss of very small RNAs. Solid-phase extraction method uses salt or 
alcohol to increase the affinity of RNA to the solid support which is glass (silica). This method 
also does not effectively recover small RNAs. The mirVana miRNA isolation process 
comprises of four steps: sample disruption in the denaturing Lysis/Binding buffer which 
stabilizes RNA and inactivates RNAse, RNA separation using Acid phenol:chloroform 1:1 to 
collect RNA in the aqueous phase, RNA purification using glass-fiber filter and wash solutions 
formulated specifically for miRNA retention to avoid the loss of small RNAs, and finally RNA 
elution to collect high quality RNA from the filter cartridge. Pre-warmed DNAse/RNAse free 
H2O was used to elute RNA. ND-1000 Spectrophotometer (NanoDrop, Wilmington, DE) was 
used to determine the quality and quantity of RNA. Total RNA collected was then used 
immediately or stored at -80
0
C. 
For regular mRNA Realtime reverse transcription analysis, the The AgPath-ID One-
Step RT-PCR Kit (Applied Biosystems/Life Techonology) was used following the 
manufacturer‟s protocol. 
For miRNA quantification, two-step Realtime RT-PCR was performed. The Taqman 
microRNA Reverse Transcription Kit (Applied Biosystems/Life Techonologies) was used to 
reverse transcribe target miRNA in 10ng of total RNA to cDNA. The primers used for this 
reverse transcription step contain a stem-loop sequence and a small sequence complementary to 
the small single strand mature miRNA. After reverse transcription, Realtime PCR was 
performed to quantify miRNA originated cDNA.  
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Name Assay ID/Sequence 
panp63 Hs00978343_m1 
ZEB1 Hs00232783_m1 
ZEB2 Hs00207691_m1 
Cyclophylin A Hs99999904_m1 
Dicer Hs00229023_m1 
Pri-miR205 Hs03302942_pri 
miR205 000509 
U6 snRNA 001973 
LOC642587 Hs03405498_m1 
SNAI2 Hs00161904_m1 
CDH2 Hs00169953_m1 
KRT5 Hs00361185_m1 
KRT14 Hs03044364_m1 
Pri1 forward primer 5‟ AAGCAATTGCAGAACACCTG 3‟ 
Pri1 reverse primer 5‟ CACCCTCTCCCTTTGTCTAGG 3‟ 
GAPDH forward primer 5‟ ACCCAGAAGACTGTGGATGG 3‟ 
GAPDH reverse primer 5‟ GAGGCAGGGATGATGTTCTG 3‟ 
P1 forward primer 5‟ GCCTGCAGAAAGACCTCTCCAT 3‟ 
P1 reverse primer 5‟ GCACCTCTCAGCAAAGCTTCAG 3‟ 
P2 forward primer 5‟ TCCAGCCTGCATGTTGGTGCT 3‟ 
P2 reverse primer 5‟ CTGTTGCTGCTCTGGCCTCT 3‟ 
P5 forward primer 5‟ CCTCAGGTCTATGGTAGATGCCCAGG 3‟ 
P5 reverse primer 5‟ GCCACATGGTCTCTCAGATATTGCCAGC 3‟ 
 Table 2: Information of primers used in the study 
60 
 
RNA expression is calculated by comparative ∆∆Ct method and displayed as relative 
quantity (RQ) ± RQ max and RQ min. Regarding endogenous control, Cyclophilin A was used 
for mRNA expression and U6snRNA was used for miRNA expression. All Taqman primers 
and probes were purchased from Applied Biosystems/Life Techonologies. The catalog numbers 
are listed in Table 1. All PCR reactions were performed using either the ABI PRISM 7500 or 
the StepOne Plus PCR systems (ABI). 
 
3. Invasion assay 
BD Biocoat
TM
 Matrigel
TM
 Invasion Chambers (BD Biosciences, San Jose, CA, 354480) 
were used to access the invasive capacity of cells in vitro. This assay was developed based on 
the classical Boyden chamber assay introduced by Boyden for the analysis of leukocyte 
chemotaxis in 1962 (184). The invasion chambers consist of a companion plate and a cell 
culture insert. The bottom of the insert is a 8-micron pore size PET membrane with a thin layer 
of MATRIGEL Basement Membrane Matrix. Matrigel is the sterile extract of the EHS tumor 
that share great similarity with the basement membrane in components and structure. The 
discovery of matrigel dates back in 1970s when a group of scientists were studying the 
components of the abundant extracellular matrix (ECM) formed by EHS (Engelbreth-Holm-
Swam) tumors, a benign mouse chrondosarcoma. They discovered that EHS tumors provide a 
large amount of basement membrane components including collagen type IV, perlecan, 
laminin, entactin and growth factors. Therefore, extract of EHS tumors which is cell-free and 
sterile – Matrigel – has been applied widely as a reconstituted form of basement membrane in 
vitro (185). Matrigel provides a barrier for non-invasive cells while presenting an appropriate 
material for invasive cells to penetrate in before passing through the membrane. This in vitro 
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setup mimics the real situation in bladder tumors where tumor cells need to degrade the 
basement membrane components to penetrate into the muscle. 
Cells in serum-free medium were seeded into invasion inserts (UC6: 25x10
3
 cells/insert, 
UC3: 15x10
3
 cells/insert) in triplicate. 3T3 conditioned medium was added in each well. This 
conditioned medium served as the chemoattractant to attract cells in the inserts. The chambers 
were incubated at 37 °C in a 5% CO2 incubator for 48 hrs. After incubation, the membrane 
surfaces facing the chemoattractant were fixed in 1% glutaraldehyde, and stained with gentian 
violet. Micrographs of the whole membranes were captured using an inverted microscope. 
Invaded cells stained in violet were counted using ImageJ software (Bethesda, MD). 
 
4. Protein overexpression and gene knockdown  
Transient KD of ΔNp63: The ΔNp63 specific siRNA 
(5‟ ACAAUGCCCAGACUCAAUU 3‟) was designed based on a previous publication (186) 
and was synthesized by Dhramacon/Thermo Scientific. The non-targeting siRNA was also 
from Dhramacon (D-001810-10-20). Lipofectamine RNAiMAX (Invitrogen/Life 
Techonologies, 13778-075) was used to transfect siRNAs into cells. Transfection procedure is 
following the manufacturer‟s instruction. Similar to transient overexpression experiment, after 
48-72 hours, cells were harvested for RNA and protein extraction 
Stable KD by virus infection: The panp63 lentiviral shRNA construct (V3LHS_397885) 
that targets all p63 isoforms and the pGIPZ empty vector (RHS4339) were purchased from 
Open Biosystems. To generate virus containing shRNA constructs, we transfected the 
constructs into 293T cells together with the packaging plasmid and the envelop plasmid. After 
48 hours, the shRNA constructs were packaged completely into infectious but replication 
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competent viral particles that escape into the 293T culture medium. 293T culture medium was 
collected and filtered to avoid any 293T cell residues. Virus concentrated from 293T medium 
was added on BC cells together with polybrene to increase the efficiency of infection. After 48 
hours, infected cells were ready for puromycin selection. Since the backbone of the two 
constructs contains puromycin resistant sequence, infected cells can survive in medium 
supplemented with puromycin. Besides, the green fluorescent protein (GFP) encoded sequence 
in the backbone also helps in sorting out the infected cells by fluorescence-activated cell sorting 
(FACS) ARIA flow cytometer (BD Biosciences). Cells containing the NT- or p63shRNA 
construct were enriched in the pooled population based on their high expression of green 
fluorescence protein (top 30%). After sorted, infected cells were maintained in medium 
supplemented with puromycin (4µg/ml). 24 hours before using cells for experiments, 
puromycin containing medium were replaced by regular medium free of puromycin.  
Transient overexpression: Lipofectamine 2000 (Invitrogen/Life Techonologies, 11668-
019) was used to transfect TAp63α (Open Biosystems/Thermo Scientific, Lafayette, CO, 
EHS1001-7380111) and ∆Np63α (GeneCopoeia, Rockville, MD, EX-Z5740-M02) into cells 
following the instructions provided by the manufacturer. After 48-72 hours, cells were 
harvested for RNA and protein extraction. 
Stable overexpression by virus infection: The ∆Np63α sequence was cut out from the 
∆Np63α-pReceiver-M02 expression vector (Genecopoeia, EX-Z5740-M02) and cloned into 
pCDH-CMV-MCS-EF1-puromycine backbone (System Biosciences). Pre-miR-205 vector was 
from System Bioscience (Mountain View, CA, CD511B-1). Virus packaging and infection 
were performed as described. The backbones of these two constructs contain puromycin 
resistant sequence. As a result, infected cells were selected in puromycin-supplemented 
medium.  
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Virus production, virus infection were performed in the MD Anderson Vector Core. 
Cell sorting was performed at MD Anderson FACS Core. 
 
5. Immunoblotting (IB)  
After washed once with PBS, cells were scraped out of 10-cm dishes and centrifuged to 
collect cell pellets. Whole cell lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM 
EDTA, 25 mM NaF, 1% Triton-X 100, 1% Nonidet P-40, 0.1 mM Na3VO4, 12.5 mM β-
glycerophosphate, 1 mM PMSF, and complete protease inhibitors) were added to the cell 
pellets. Cell lysis were proceeded on and end-to-end rotator at 4
0
C in 1 hour. Whole cell lysates 
were clarified at 13,000 rpm for 5 min before resolved on SDS-PAGE gels. Gel concentration 
depends on the molecular weight of target proteins. 6% SDS-PAGE gels were used for ZEB1 
(200 kDa), 8% SDS-PAGE gels were for N-Cadherin (135 kDa), 10% SDS- polyacrylamide 
gel electrophoresis (PAGE) gels were for p63, and 12% SDS-PAGE gels were for Slug (34 
kDa). Proteins were transferred onto nitrocellular membranes at 100 Volt in 1.5-2 hours. 
Primary antibody incubation was performed at 4
0
C on the shaker overnight. Secondary 
antibody incubation was at room temperature on the shaker for 1 hour. Antibodies used for IB 
were anti-panp63 (clone 4A4, Santa Cruz Biotechnology, Santa Cruz, CA), anti-ZEB1 (Cell 
Signaling, Boston, MA), anti-N-cadherin (Life Technologies), and anti-Slug (Santa Cruz 
Biotechnology). Detailed information about the antibodies used in this study is in Table 3.  
 
6. Flow cytometry 
Since the targets for cell surface staining flow cytometry are two adhesion molecules: 
N-cadherin and P-cadherin, 100mM EDTA was used to detach cells instead of Trypsin, which 
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can cleave adhesion molecules on the cell surface. Cells were washed once with PBS and then 
blocked in incubation buffer containing 0.5% bovine serum albumin – BSA. For N-cadherin 
detection, a direct staining method was employed using an allophycocyanin (APC)-conjugated 
anti-human N-cadherin antibody (R&D Systems, Minneapolis, MN, FAB6426A) following the 
company‟s protocol in which cells were incubated with the APC-conjugated antibody for 1 
hour at room temperature, washed twice with PBS, resuspended in PBS and then analyzed by 
flow cytometer. Negative control for N-cadherin staining is APC-conjugated sheep IgG. For P-
cadherin detection, indirect staining was performed using a polyclonal rabbit anti-P-cadherin 
antibody (Cell Signaling, Boston, MA, 2130) and Alexa Fluor 594-conjugated goat anti-rabbit 
IgG (H+L) (Invitrogen/Life Technology, A11037). Cells were incubated with the primary 
antibody for 1 hour at room temperature, washed twice with PBS, incubated with secondary 
antibody 30 minutes at room temperature, washed and resuspended in PBS, and then analyzed 
by flow cytometer. Negative control samples were stained with the secondary antibody alone. 
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Antibodies Indication Condition Company  Catalog number 
panp63 (4A4) IB 1:1000 in 5% 
milk 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
sc-8431 
ZEB1 IB 1:1000 in 5% 
BSA 
Cell Signaling, 
Boston, MA 
3396 
N-cadherin IB 1:1000 in 5% 
milk 
Invitrogen/Life 
Technologies, 
Grand Island, 
NY 
33-3900 
Slug IB 1:1000 in 5% 
milk 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
sc-15391 
p53 ChIP 2ug Millipore, 
Billirica, MA 
17-613 
Pol II ChIP 1ug Millipore, 
Billirica, MA 
17-620 
Normal mouse 
IgG 
ChIP 1ug Millipore, 
Billirica, MA 
12-371B 
Table 3: Information of antibodies used in the study 
 
7. Chromatin-Immunoprecipitation (ChIP) Assay 
The ChIP-IT-Express kit from Active Motif (Carlsbad, CA, 53009) was used to for the 
ChIP assay. Cells were grown in 15-cm dishes until 80% - 90% confluent. Cell fixation step 
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were performed in media containing 1% formaldehyde for 10 minutes at room temperature. 
This step allowed DNA cross-link to proteins such as histones, transcription factors and other 
DNA-associated proteins. The fixation step was stopped by adding the stop-fix solution 
containing Glycine. Cells were then scraped from the dishes and pelleted by centrifugation for 
10 minutes at 2,500 rpm at 4
0
C. Cell lysis buffer supplemented with protease inhibitor cocktail 
and PMSF was used to lyse cells for 1 hour on ice. Douncing on ice with 50 strokes using a 
dounce homogenizer was applied to aid in nuclei releases. Chromatin in nuclei pellet was then 
subjected to enzymatic fragmentation. The enzymatic shearing cocktail (200 U/ml) was added 
to the pre-warmed nuclei in digestion buffer, followed by 20 minutes incubation at 37
0
C. 
Shearing reaction was stopped by adding ice-cold 05M EDTA. Shearing efficiency was 
examined by DNA gel electrophoresis. Optimized shearing reaction will yield bands between 
200-1500 bp. Appropriately sheared chromatin were subjected to immunoprecipitation using 
antibodies of interest and magnetic beads. Detailed information regarding antibodies used for 
ChIP is listed in Table 3. For each ChIP reaction, 1-8 µg of antibody was used. Chromatin were 
the eluted from the magnetic bead – antibody – protein complex and DNA fragments was 
released after reverse cross-linked at 65
0
C for 4 hours. Proteinase K was used to eliminate 
protein in the final products. Precipitated DNA was quantified and normalized to DNA input by 
quantitative real-time PCR with SYBR green qPCR master mix (Applied Biosytems/Life 
Techonologies). Sequence of primers used for ChIP was listed in Table. The relative 
enrichment of target sequences precipitated by antibody bound magnetic beads is demonstrated 
as RQ value (RQ = 2
-ΔCtx100; ΔCt = Ct(ChIP) – Ct(Input)). Real-time-PCR reactions were 
performed in triplicate and the results are presented as mean ± SD for the triplicate samples. 
Data are representative of two to three independent experiments. 
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8. Nuclear run-on 
Nuclear run-on experiments were proceeded as described in the short technical report 
(187) with minor modification. Briefly in this experiment, cellular nuclei were isolated and 
induced for transcription to happen, nascent transcribed RNA was isolated and analyzed. To 
collect nuclei, cell pellets was lysed in mild lysis buffer (10mM Tris-HCl, pH 7.4, 3mM MgCl2, 
10mM NaCl, 150mM sucrose and 0.5% Nonidet P-40) to break the cell membrane but leave 
the nuclear membrane intact. Nuclei were collected by centrifugation and in vitro RNA 
synthesis was performed at 29
0
C for 30 minutes in the transcription buffer (100mM KCl, 
20mM Tris-HCl, pH 8.0, 5mM MgCl2, 4mM dithiothreitol (DTT), 200mM sucrose and 20% 
glycerol). Materials for RNA synthesis including rATP, rGTP and rCTP (Epicenter 
Biotechnologies, Madison, WI, RN02825) were also added to the transcription buffer. 
Especially, instead of using regular rUTP, biotin-16-UTP (Epicenter Biotechnologies, 
BU6105H) was provided in the transcription buffer. Reactions were then halted by adding a 
“stop” buffer containing 250mM CaCl2, and 10 units/µl DNase I (Roche Applied Science, 
Indianapolis, IN) which aids in eliminating DNA in the reaction. Nuclei were then lysed and 
RNA was extracted using mirVana™ miRNA Isolation Kit (Ambion/Life Techonologies). 
Biotin labeled nascent transcribed RNA was precipitated using magnetic beads coated with 
streptavidin (Dynabeads® M-280 Streptavidin, Invitrogen/Life Techonologies, 112.05D). 
Reverse transcription was performed using the high capacity cDNA reverse transcription kits 
(Applied Biosystems/Life Techonologies) to generate cDNA from the precipitated RNA. Fast 
SYBR Green master mix (Applied Biosystems/Life Techonologies) was used for qPCR 
analysis. Primers for the nuclear run-on experiment are described in Table 1. 
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9. Human specimens 
Flash frozen tissue from 98 patients was obtained from the MD Anderson Genitourinary 
Cancer tissue bank. Samples were collected by microdissection focusing on areas with at least 
80% tumor concentration to enrich the tumor content in the samples. All samples were 
examined by a pathologist to ensure the tumor enrichment. All patients whose samples were 
used in this study had previously been signed informed consent allowing collection of their 
tissue and clinical data in our genitourinary research database. Patients were classified as 
muscle-invasive if their tumors had grown into the muscularis propria (stage ≥T2); otherwise, 
they were classified as superficial (non muscle-invasive) (stage Ta or T1). mirVana™ miRNA 
Isolation Kit (Ambion/Life Techonologies) was used to extract total RNA from all the samples 
 
10. Statistical Methods 
mRNA expression data from qRT-PCR were used to analyze the correlations between 
p63 and mir205 and to evaluate the association between mir205 and overall survival (OS) and 
disease-specific survival (DSS). Spearman‟s rho coefficient analysis was used to determine the 
correlations among expression of markers. The cutoff point to classify high and low mir205 
was defined by regression tree analysis. The Kaplan-Meier curves were generated to 
demonstrate the survival distribution of patients based on their mir205 expression characterized 
as high and low. We used the log-rank test to compare survival distributions between groups. 
The Cox proportional hazards model was used to assess the effects of multiple markers on DSS 
and OS, adjusting for other important covariates. All p-values presented are 2-sided. p-values 
less than 0.05 were considered to be statistically significant. Statistical analyses were 
performed using Splus 7 (Insightful Corp, Seattle, WA). 
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1. ∆Np63α is the most abundant isoform in human bladder cancer (BC) cell lines 
p63 is a transcription factor with multiple downstream targets. Six isoforms of p63 can 
have the same or different targets and the effects that these isoforms have on their downstream 
targets can be additive or opposite. As a result, we first characterized the p63 isoforms in a 
panel of human bladder cancer cell lines (n=28) using quantitative real time PCR (qRT-PCR) 
with the panp63 primer that recognize all 6 isoforms as well as the ∆N- and TA- primers that 
are specific for the ∆N- and the TA- isoforms, respectively. Interestingly, the expression pattern 
of ∆Np63 and panp63 in all the cell lines tested (Fig. 10A a and b) are very similar, while the 
expression pattern of TAp63 (Fig. 10A c) is not very much similar to that of ∆N- and panp63. 
We also compare the expression of TA- and ∆Np63 in each cell lines. Provided that primer 
efficiency affect the sensitivity of PCR reactions, we characterized the efficiency of the TA- 
and ∆Np63 primer as described in (reference) and calculated the relative quantity (RQ) value 
based on normalized primer efficiency. PCR results show that the expression of ∆Np63 (black 
bar) is substantially higher than that of TAp63 (empty bars) in majority of the cell lines (Fig. 
10A d). Moreover, panp63 and ∆Np63 cluster together while TAp63 is separated from the other 
two in the heatmap generated from the PCR data (Fig. 10B). All of these data clearly show that 
∆Np63 is the most abundant isoform group on BC cell lines. 
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Figure 10: ∆Np63 is the predominant isoform group in BC. (A) qRT-PCR quantification of 
panp63 (a), ∆Np63 (b), TAp63 (c), and TA-and ∆Np63 (d) in BC cell lines (n=28). Bars 
display the relative quantities (RQ) of gene expression ± RQ max and RQ min. (B) Heatmap 
generated from the RQ value of panp63, ∆Np63, TAp63 mRNA expression measured by qRT-
PCR. Spearman correlation coefficient analysis results demonstrate the strong correlation 
between panp63 and ∆Np63. The correlation between panp63 and TAp63, ∆Np63 and TAp63 
are statistical significant. However, the correlation between panp63 and ∆Np63 is the strongest.  
 
 
 
 
 
 
Figure 11: ∆Np63α is most abundant isoform in BC. (A) IB for p63 expression in BC cell 
lines (n=14). The 4A4 p63 antibody recognizes all p63 isoforms. (B) Molecular weight of 
∆Np63α and TAp63α isoform. P63 protein in UC14 cell line migrates to the same position with 
∆Np63α isoform. 
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To confirm the expression of p63 at the protein level, the monoclonal mouse anti-p63 
antibody (clone 4A4) was used to detect the protein expression of all six p63 isoforms in 14 
representative cell lines. Consistent with mRNA expression data, cell lines with high p63 
mRNA show high p63 protein level identified by a strong band migrating at 75kDa whereas 
cell lines with low p63 mRNA show low or undetected p63 protein level (Fig. 11A). Among 
six p63 isoforms, the molecular weight of ∆Np63α, TAp63α and TAp63β are approximately 
75kDa (188). Since ∆Np63 is the most abundant group of isoforms in BC cell lines, we expect 
that∆Np63α is the isoform responsible for the 75kDa band. To test this idea more directly, we 
overexpressed TAp63α and ∆Np63α in UC3, a cell line with very low endogenous p63 
expression, and examined p63 expression by the 4A4 antibody (Fig. 11B). The Western blot 
(WB) result clearly verify that the 75kDa band is ∆Np63α.  
In summary, mRNA and protein expression analysis demonstrate that ∆Np63α is the 
most abundant isoform in BC cell lines.  
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2. ∆Np63α inhibits epithelial-mesenchymal transition (EMT) 
Our previous publications reveal a correlation between ∆Np63 and E-cadherin in BC 
cell lines (n=15) as well as in human primary tumors (145,189), suggesting that ∆Np63 
associates with the epithelial phenotype. In addition, p63 is well known for its role in epithelial 
stem cell homeostasis (190,191). Interestingly, stem cell properties are identified in cells that 
have undergone EMT (72), indicating that messenchymal cells possess stemness. As a result, 
the role of p63 in EMT becomes an attractive topic to explore. Our first step to learn about p63 
and EMT was to characterize the expression of p63 and crucial EMT players (E-cadherin, 
ZEB1 and ZEB2) in our panel of 28 BC cell lines. Consistent with our previously published 
data, panp63, ∆Np63 and E-cadherin (CDH1) clustered together while ZEB1 and ZEB2 
clustered together, demonstrating the close correlation between molecules in each cluster as 
well as the inverse correlation between the two clusters (Fig. 12). 
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Figure 12: Correlation between ZEB1and ZEB2; CDH1, ∆Np63 and panp63. Heatmap 
generated from the RQ value of CDH1, panp63, ∆Np63, ZEB1 and ZEB2 mRNA expression 
measured by qRT-PCR. Spearman correlation coefficient analysis results demonstrate the 
statistical significant correlation between CDH1, panp63 and ∆Np63; and between ZEB1 and 
ZEB2. There is no correlation between CDH1/panp63/∆Np63 and ZEB1/2. 
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In order to study the functions of p63, we stably knocked down (KD) panp63 in an 
“epithelial” cell line (UC6) using a shRNA construct that targets all the p63 isoforms. As we 
had determined in Figs. 10 and 11 that ∆Np63α is the most abundant isoform of p63 in BC 
cells, we concluded that the shRNA construct mainly targets ∆Np63α. We also stably 
overexpressed ∆Np63α in a “mesenchymal” cell line, UC3, which has very low endogenous 
p63 expression. Strikingly, UC6 ∆Np63αKD cells acquired mesenchymal properties while UC3 
∆Np63α overexpressing cells gained epithelial traits. Regarding the morphology, UC6 
∆Np63αKD cells changed from the typical epithelial polygonal shape to elongated fibroblast-
like shape. While wild-type (WT) and non-targeting (NT – cells infected with the empty 
vector) UC6 cells grew in discrete groups of cells, UC6 ∆Np63αKD cells tended to spread out 
and grow as individual cells. UC3 ∆Np63α overexpressing cells, on the other hand, obtained a 
morphology resembling “epithelial” cells (Fig. 13A). Regarding functional changes of cells 
undergoing EMT, an increase in invasion capacity is common. The loss of cell-cell and cell-
basement membrane contact, the change in morphology to become more fibroblast-like, the 
loss of polarity, and the ability to degrade the extracellular matrix provide the cancer cells that 
have undergone EMT with the ability to invade through the basement membrane into the 
muscle and finally extravasate into the circulation. Therefore, we performed invasion assays to 
examine the invasive capacities of the ∆Np63α KD and overexpressing cells. In line with the 
effects of ∆Np63α modulation on morphology, the UC6 ∆Np63αKD cells exhibited an increase 
in their ability to invade through the matrigel membrane compared to the NT and the WT cells, 
whereas UC3 ∆Np63α overexpressing cells show a significant decrease in invasion compared 
to the empty-vector-infected (Vec) and the WT counterparts (Fig 13B). 
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Figure 13: Modulation of ∆Np63α expression alters the morphology and the invasive 
capacity of BC cells. (A) Cell morphology observed under bright field microscope. 
∆Np63αKD UC6 cells have mesenchymal morphology while ∆Np63α overexpressing UC3 
have epithelial morphology. (B) Invasion assay demonstrating the effect of ∆Np63α 
modulation in the invasive capacity of cells. Pictures show cells that have invaded through the 
matrigel membrane of the invasion chamber. Quantification of invaded cells was demonstrated 
in the graph. Bars represent mean ± SEM from triplicate wells, Student t test, *p<0.05 and 
**p<0.01  
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At the molecular lever, EMT is usually characterized by the gain in the expression of 
messenchymal markers and the loss of epithelial markers. We examined the effect of 
modulating ∆Np63α on the expression of the epithelial markers CK-5 and CK-14, as well as 
the mesenchymal markers ZEB1/2, N-cadherin, and Slug in UC6 and UC3. Both qRT-PCR and 
immunoblotting revealed down-regulation of the epithelial markers (CK-5/14) and up-
regulation of mesenchymal markers (ZEB1/2 and N-cadherin) in the UC6 ∆Np63α KD cells 
(expression reduced 80-90%). The opposite effects were observed in UC3 cells with enforced 
∆Np63α expression (Fig. 14).  
Cadherins are a family of calcium dependent transmembrane glycoproteins mediating 
cell-cell and cell-ECM adhesion. As major adhesion molecules, cadherins play crucial roles in 
development and carcinogenesis (192). P-cadherin specifically localize to the basal cells of 
normal bladder and normal prostate tissue (193,194). Therefore, P-cadherin is considered as a 
basal cell-specific epithelial marker, at least in the bladder and the prostate. N-cadherin, on the 
other hand, is a well-characterized mesenchymal marker. Increased expression of N-cadherin is 
commonly used as a marker of EMT (195). Interestingly, N-cadherin is not expressed in normal 
bladder urothelium but abnormally present in bladder tumors (193). To determine if ∆Np63α 
modulation affects EMT, we measured the presence of P-cadherin and/or N-cadherin protein on 
the surface of ∆Np63αKD UC6 cells by two-color cell surface staining and flow cytometry 
(FACS). UC6NT cells were double-positive for P- and N-cadherin, indicating an intermediate 
phenotype of cells partially undergoing EMT (1,196). ∆Np63α knockdown reduced the cell 
surface expression of P-cadherin and increased the surface expression of N-cadherin (Fig. 
15A), generating a new population of cells that was negative for P-cadherin and positive of N-
cadherin (Fig. 15B). These results demonstrate that ∆Np63α knockdown functionally 
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modulates the pool of P- and N-cadherin across the entire population of UC6 cells, promoting 
the mesenchymal phenotype.  
Slug (SNAI2) is the only mesenchymal marker that did not conform to the pattern. Slug 
expression decreased in ∆Np63KD cells and increased in ∆Np63 overexpressing cells, 
indicating a hint of a pro-EMT effect of ∆Np63α (Fig. 14). We confirmed the effect of ∆Np63α 
in 4 other “epithelial” BC cells:  UC14, UC17, UC5, and SW780. With 70-80% KD efficiency, 
a decrease in ∆Np63α also resulted in a decrease in Slug expression (Fig. 16). The effect of 
∆Np63α on Slug expression suggests that ∆Np63α can facilitate the mesenchymal phenotype, 
which was reported in a recent publication (197). This observation helps explain the 
intermediate EMT phenotype of UC6 NT cells which strongly express ∆Np63α (Fig. 15). 
However, the overall impact of ∆Np63α on the morphology, invasion, and the majority of the 
epithelial and mesenchymal markers we tested clearly demonstrates that ∆Np63α suppresses 
EMT in BC cells. 
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Figure 14: ΔNp63α modulation alters expression of multiple epithelial and mesenchymal 
markers. (A) qRT-PCR result showing mRNA expression of the epithelial markers (CK-5, CK14) and 
the mesenchymal markers (ZEB1/2, Slug, N-cadherin) as well as panp63 in ΔNp63α knockdown UC6 
(ΔNp63αKD) and ΔNp63α overexpressing UC3 cells. Bars show the RQ of gene expression ± RQ max 
and RQ min. (B) IB showing protein expression of the mesenchymal markers (ZEB1, N-cadherin and 
Slug) and ∆Np63α in ΔNp63α knockdown UC6 (ΔNp63αKD) and ΔNp63α overexpressing UC3 cells. * 
denotes non-specific bands.  
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Figure 15: ∆Np63α knock down reduces P-cadherin and induces N-cadherin on the cell surface. 
(A) cell surface P-cadherin (left) and N-cadherin (right) measured by flow cytometry. P-cadherin was 
labeled with Alexa Fluor 594 and N-cadherin was labeled with allophycocyanin (APC). Statistical 
analysis shows the differences in surface protein expression by mean and median fluorescence intensity. 
(B) Dual color staining for both P- and N-cadherin in the same samples. The negative control was used 
to set the gate for each target protein. 
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Figure 16: ∆Np63α knockdown results in downregulation of Slug. qRT-PCR results demonstrating 
down regulation of Slug mRNA expression in four ∆Np63αKD BC cell lines. The bars show the RQ of 
gene expression ± RQ max and RQ min. 
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3. ∆Np63α expression strongly correlates with the expression of the primary and mature 
forms of miR-205 in BC cell lines and primary tumors 
The observation that ∆Np63α suppressed ZEB1/2 expression encouraged us to explore 
the relationship between these molecules. Since p63 can bind to p53 response elements 
(p53REs) to regulate the expression of its downstream targets, we first searched for p53REs on 
the promoter regions of ZEB1/2 but failed to find any, indicating that p63 may indirectly 
regulate the expression of ZEB1/2. It is now well known that the mir200 family functions as 
suppressors of ZEB1/2. In 2010, Mien-Chie Hung‟s group reported that p53 regulates EMT by 
inducing miR200c (68). We therefore measured the expression of mir200 family members in 
the UC6 and UC14 ∆Np63αKD cells but did not observe downregulation of miR200c or any 
other miR200 family members in either of the cell lines. Therefore, we carefully examined 
gene expression profiling data (Illumina HT12V4 chips) obtained from the WT, NT and 
∆Np63KD UC6 and UC14 cells to look for changes in molecules potentially involved in EMT 
regulation. Interestingly, we found out that the primary form of miR-205 was down regulated in 
both ∆Np63KD cell lines. Because miR-205 is similar to the miR200 family in terms of its 
ability to bind to the ZEB1/2 mRNAs and inhibit their expression (33,35), we decided to focus 
our research on defining the relationships among p63, miR-205 and ZEB1/2. 
Strikingly, gene expression profiling data of our BC cell lines panel revealed a strong 
correlation between the expression of p63 and the primary form of miR-205. By performing 
qRT-PCR using panp63, ∆Np63 primers and the primers specific for the primary (pri-) and the 
mature forms of miR-205, we confirmed the strong correlation among these molecules.  A 
heatmap generated using the relative quantity (RQ) values of gene expression clearly showed 
the correlation in the expression patterns of these molecules in BC cell lines. Statistical analysis 
using Spearman‟s rho coefficients showed the significance in the correlation among these 
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molecules (Spearman rho>0.8, p<0.0001) (Fig. 17A). In general, after being transcribed by 
RNA Polymerase II to generate the primary form, microRNAs go through multiple steps of the 
microRNA processing to become mature microRNA. Any dysregulation of microRNA 
processing can result in abnormal expression of mature microRNAs. The similarity in 
expression patterns of the primary and mature forms of miR-205 suggests that this microRNA 
is regulated mainly at the transcription step rather than the processing steps (Fig. 17B). 
The similarity in expression patterns of p63 and miR-205 was also observed in primary 
bladder tumors. Specimens from 98 patients including both superficial (n=32) and muscle 
invasive (n=66) bladder tumors were examined for expression of panp63 and mature miR-205 
by qRT-PCR. Statistical significant correlation (Spearman rho=0.44, p<0.00001) was detected 
(Fig. 18), suggesting the co-expression of p63 and miR-205 in the tumors.  
The correlation in p63 and miR-205 expression in BC cell lines and primary bladder 
tumors, identified by gene expression profiling and qRT-PCR, strongly implicates p63 in 
transcriptional regulation of miR-205. As determined in Fig. 10, Fig. 11 and previous 
publications (143,145) that established that ∆Np63α is the major isoform expressed in BC cell 
lines and primary tumors, we hypothesized that ∆Np63α is the isoform involved in 
transcriptional control of miR-205. 
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Figure 17: Correlation between p63 and pri-/mature miR-205. (A) Heatmap generated from 
qRT-PCR data showing the strong correlation among panp63, ∆Np63, pri-miR-205 and mature 
miR-205 in BC cell lines (n=28). Statistical analysis using Spearman method confirms the 
statistical significant of the correlation. (B) qRT-PCR data in bar graph demonstrating the 
strong correlation between the primary form and the mature form on miR-205. Bars show the RQ 
of gene expression ± RQ max and RQ min. 
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Figure 18: Correlation between p63 and miR-205 in patients. Heatmap generated from 
qRT-PCR data showing the correlation among panp63 and mature miR-205 in BC patient 
samples (n=98). Statistical analysis using Spearman method confirms the statistical 
significance of the correlation.  
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4. ∆Np63α regulates ZEB1/2 expression by through modulation of miR-205 
Since ∆Np63α modulation resulted in inverse changes in ZEB1/2 and ∆Np63α 
expression correlated with miR-205, a negative regulator of ZEB1/2, we examined the 
expression of miR-205 in ∆Np63αKD and overexpressing cells. As we expected, mRNA 
expression of primary and mature forms of miR-205 decreased in ∆Np63αKD UC6 and 
increased in ∆Np63α overexpressing UC3 cells (Fig. 19A). This qRT-PCR result is consistent 
with the gene expression profiling data we had obtained with the UC6 ∆Np63αKD cells. We 
also checked miR-205 (primary and mature) expression in 4 other ∆Np63αKD cell lines 
(UC14, UC17, UC5 and SW780) and the obtained the same result, that down regulation of 
∆Np63α decreased miR-205 expression (Fig. 19B). 
Prolonged down-regulation of a gene by shRNA infection may have off-target effects. 
To validate the effect of ∆Np63αKD on mir-205, we transiently knocked down ∆Np63 in the 
UC6 cells using a ∆Np63-specific siRNA. The specificity and efficiency of the ∆Np63 specific 
siRNA was demonstrated by 70% decrease in ∆Np63 expression and no significant change in 
TAp63 expression. Similar to the effect of ∆Np63α stable KD, ∆Np63 transient KD also 
resulted in decreased expression of miR-205, demonstrating that miR-205 is indeed a 
downstream target of ∆Np63α (Fig. 20) 
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Figure 19: Expression of the primary and the mature form of miR-205 change in parallel 
with ∆Np63α alteration. (A) qRT-PCR results showing pri- and mature miR-205 are down-
regulated or up-regulated in ∆Np63αKD UC6 or ∆Np63α overexpressed UC3, respectively. (B) 
Down-regulation of pri- and mature miR-205 when ∆Np63α is knocked down in four BC cell 
lines. Bars show the RQ of gene expression ± RQ max and RQ min.  
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Figure 20: Down regulation of miR-205 in UC6 cells, in which ∆Np63 is transiently 
knocked down. qRT-PCR data show that the ∆Np63 transient knockdown is specific and that 
miR-205 expression is reduced in the KD cells compared to the cells transfected with the 
control siRNA. Bars show the RQ of gene expression ± RQ max and RQ min. 
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Even though miR-205 is known as a negative regulator of ZEB1/2, there is no report 
regarding this effect of miR-205 in BC. Therefore, we overexpressed the precursor form of 
miR-205 in ∆Np63αKD UC6 cells and examined the expression of ZEB1/2 to determine if 
decreased miR-205 mediates the effect of ∆Np63αKD on ZEB1/2 expression. The infection of 
virus carrying miR-205 precursor construct induced miR-205 expression in the UC6 
∆Np63αKD cells to 5 fold higher than the UC6 WT cells while the virus carrying the empty 
vector control did not affect miR-205 expression. p63 expression in the ∆Np63αKD UC6 cells 
infected with either empty vector or miR-205 virus remained lower than in the WT and NT 
cells (Fig. 21A). As we expected, overexpression of exogenous miR-205 largely reversed the 
induction of ZEB1/2 generated by ∆Np63αKD at both RNA and protein level (Fig. 21B). As 
ZEB1/2 are the two canonical EMT regulators, this result clearly proves the important role of 
miR-205 in mediating the effects of ∆Np63αKD on EMT. The relationship between ∆Np63α 
and EMT is generalized in Fig. 22 
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Figure 21: ∆Np63α regulates ZEB1/2 via miR-205. (A) qRT-PCR results showing that 
expression of panp63 remained unchanged while miR-205 expression was strongly enhanced in 
miR-205 overexpressing ∆Np63KD UC6 cells. (B) miR-205 overexpression reversed the effect 
of ∆Np63αKD on ZEB1/2. qRT-PCR and IB data demonstrate that the induction ZEB1/2  
mRNA and protein by ∆Np63αKD was abrogated by miR-205 overexpression.  
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Figure 22: Schematic illustration of the relationship between ∆Np63α, miR-205, ZEB1/2 
and EMT 
 
 
 
93 
 
5. ∆Np63α regulates miR-205 via miR-205HG 
Since they were discovered in 1993 in C.elegans (198), miRNAs have become more 
and more attractive to scientists for their multiple impacts in all aspects of cell biology. miRNA 
processing from pri-miRNAs to pre-miRNAs and finally to mature miRNAs has been explored 
in detail in multiple cell models. However, little is known about the transcription process to 
generate pri-miRNAs. Based on genomic loci, miRNAs can be classified into two groups: 
intergenic miRNAs and intragenic miRNAs. Intergenic miRNAs are those located in between 
genes and are controlled as independent transcriptional units. On the other hand, intragenic 
miRNAs reside within protein coding genes that are referred to as the “host” genes for the 
miRNAs (199). The similarity in the expression patterns of miRNAs and their “host” genes 
indicates that this class of miRNAs is transcribed along with their “host” genes (81,200). MiR-
205 is an intragenic miRNA. Its genomic location overlaps the junction between the last intron 
and the last exon of a poorly characterized protein-coding gene (Fig. 23). This protein- coding 
gene, formerly known as LOC642587, has been termed miR-205 “host” gene (miR-205HG). 
Since miR-205 is potentially transcribed along with miR-205HG, we performed qRT-PCR to 
examine the expression of miR-205HG in ∆Np63α-modulated cells using primers spanning the 
exon 2 and 3 junction. Interestingly, miR-205HG expression decreased in all five ∆Np63α KD 
cells and increased in UC3 ∆Np63α overexpressed cells (Fig. 24). These data confirm the 
connection between miR-205 and miR-205HG in RNA expression and the important role of 
∆Np63α in their mutual regulation. 
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Figure 23: Genomic location of miR-205 is inside miR-205HG 
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Figure 24: Expression of the miR-205 host gene (miR-205HG) changes in parallel with 
∆Np63α alteration. qRT-PCR results showing miR-205HG mRNA levels were down-
regulated and upregulated in ∆Np63αKD or ∆Np63α overexpressed cells, respectively. The 
Taqman probe for miR-205HG spans the junction of exon 2 and 3. Bars show the RQ of gene 
expression ± RQ max and RQ min.  
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The steady state of mRNA/pri-miRNA detected by qRT-PCR is the balance between the 
generation of new mRNA/pri-RNA and mRNA/pri-RNA degradation. To determine if ∆Np63α 
is involved in the transcription of miR-205 and miR-205HG per se, we performed nuclear run-
on experiments, which allowed us to compare the quantities of nascent transcripts. In this 
experiment, short-time transcription induction in vitro allowed endogenous RNA Poll II to 
complete the elongation step of transcription without any de novo transcription initiation. 
Therefore, the quantity of nascent transcripts is proportional to the number of Pol II molecules 
that are bound to the gene of interest. By replacing rUTP with biotinylated-rUTP, this method 
enabled us to pull down the nascent transcript using streptavidin coated magnetic beads. 
Subsequent reverse transcription and real time PCR provided us quantifiable comparisons 
between the transcription rates of samples. The nuclear run-on results showed decreases in the 
miR-205HG and pri-miR-205 transcription rates in UC6 ∆Np63α KD cells, demonstrating the 
crucial role of ∆Np63α in the transcription of miR-205HG and pri-miR-205 (Fig. 25). 
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Figure 25: The transcription of miR-205HG and miR-205 is suppressed in ∆Np63kd cells. 
Real time PCR data show the expression of miR-205HG and pri-miR-205 in nuclear run-on 
experiments measuring the nascent transcripts generated from miR-205HG and miR-205. HG1 
primers were designed within exon 1 of miR-205HG. Pri1 primers were designed to detect the 
same amplicon with the pri-miR-205 primers from ABI. GAPDH expression was used as an 
endogenous control 
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Even though intragenic miRNAs are thought to be transcribed together with their “host” 
genes, some recent publications reveal that intragenic miRNAs have their own promoters and 
transcription start sites (TSS) and can be transcribed independently of their “host” genes 
(82,83). In most of the cases, miRNAs are transcribed by RNA Pol II (except for some miRNA 
transcribed by RNA Pol III (201)). We used an anti-RNA Pol II antibody and chromatin 
immunoprecipitation (ChIP) to determine whether miR-205 is transcribed with miR-205HG. 
We designed three primer sets, one in Region 1 encompassing 1kb upstream of the miR-205HG 
TSS, one in Region 2 encompassing 1kb upstream of the miR-205 start site and the last one in 
Region 5 located 5kb away from miR-205HG (Fig. 26A). Primers for the promoter of GAPDH 
were used as a positive control, and primers for Region 5 were use as a negative control. As 
RNA polymerase pausing happens at the transcription initiation step to facilitate the time-
consuming assembly of the transcription initiation complex at the promoters of genes, RNA Pol 
II is bound to the promoters of gene tested in this assay.  The ChIP results showed an 
enrichment of Pol II at Region 1 comparable to Pol II enrichment at GAPDH promoter while 
Pol II enrichment at Regions 2 and 3 was minimal (Fig. 26B), suggesting that Region 1 is the 
promoter of both miR-205HG and miR-205. Therefore, we conclude that miR-205 is 
transcribed along with its “host” gene. 
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Figure 26: The promoter of miR-205HG is also the promoter of miR-205. (A) Map 
showing the genomic positions of miR-205 and miR-205HG in detail. Location of primers 
designed for ChIP experiment (P1, P2, and P5) is illustrated. The positions were numbered 
based on the potential transcription start site (TSS) directly 5‟ of miR-205 (in red, below) or 
based on the TSS of the miR-205 host gene (miR-205HG, in black, above). (B) Pol II binds to 
region 1 which is the promoter of miR-205HG. Real time PCR data show Chromatin 
Immunoprecipitation (ChIP) results. Primers detecting the promoter of GAPDH are used as 
positive control. IgG is the negative control. Bars represent mean ± SD of normalized RQ 
values in triplicate samples. 
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When analyzing the sequence of miR-205HG and its surrounding areas using the 
University of California Santa Cruz (UCSC) genome browser (www.genome.ucsc.edu), I 
discovered that Region 2 is highly conserved across 46 vertebrate species and hypersensitive to 
DNAse, similar to Region 1, which is the promoter of miR-205HG (Fig. 27B). Due to their 
important roles in regulating gene expression, regulatory regions such as promoters and 
enhancers are highly conserved during evolution. Regulatory regions are also usually in an 
“open” state with minimal contacts with the histones to facilitate the access of the bulky 
transcriptional machinery to chromatin. Therefore, these regions are hypersensitive to DNAse 
treatment. The conservation and DNAse sensitivity of Region 2 indicates its likely role as a 
regulatory region for miR-205 and miR-205HG. Interestingly, I also identified a p53 response 
element (p53RE) in Region 2 by the Genome Browser and Genomatix. A canonical p53RE 
consists of a tandem repeats of a 10bp consensus binding motifs 5‟ 
PuPuPuC(A/T)(A/T)GPyPyPy 3‟, separated by a 0-13bp spacer (202). Each binding motif is a 
half-site of a whole-site p53RE. The three purines and three pyrimidines flanking the half-site 
are flanking sequences. C(A/T)(A/T)G is the core sequence of the motif. The p53RE I 
identified in Region 2 of miR-205HG is a whole-site p53RE strongly homologous to the 
canonical sequence with only one nucleotide mismatch at the flanking sequence (Fig. 27A). As 
a member of the p53 family, p63 exhibits remarkable sequence and structural homology to p53, 
especially in the DNA binding domain, suggesting overlaps in target recognition specificity. 
Indeed, p63 can bind to p53 response elements (p53REs) in vitro and in vivo (147). I performed 
ChIP using the 4A4 antibody and discovered that ∆Np63α binds to Region 2 of miR-205HG 
(Fig. 28A). The enrichment of ∆Np63α at Region 2 is significantly reduced in ∆Np63αKD 
cells, suggesting that this binding is specific (Fig. 28B). As a result, Region 2 appears to be a 
very important regulatory region of miR-205 and miR-205HG that is bound by ∆Np63α. 
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Figure 27: Region 2 containing a whole-site p53 response element (p53RE) is a regulatory 
region. (A) Detailed information regarding the p53RE in region 2. Comparison between the 
consensus p53 binding site and the p53RE in region 2 reveals only one mismatch (in lower 
case) in the second flanking sequence. (B) Region 2 is highly conserved and hypersensitive to 
DNAse. Sequence of Region 2 is blatted in UCSC Genome Browser. Evolutionary 
conservation among 46 vertebrate species is measure by the PhyloP method. Positive scores (in 
blue) are assigned to conserved sties, while negative scores (in red) are assigned to fast-
evolving sites. DNAse hypersensitive regions tested in a large number of cell lines are shown in 
the DNAse hypersensitivity tract. The intensity of shading in the grey boxes represents the 
extent of DNAse hypersensitivity of specific regions (proportional to the signal strength) in the 
cell lines tested. The number on the left side of the box is the number of cell lines tested. The 
transcription factor binding site tract (TFBS) shows the sites that are conserved in human, 
mouse, and rat. 
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Figure 28: ∆Np63α binds to region 2. (A) Real time PCR data from ChIP experiments 
showing that ∆Np63α binds to region 2. Histone H3 antibody was used as a positive control. 
IgG was used as a negative control. (B) Decreased binding of ∆Np63α to region 2 in ∆Np63α 
KD cells. Bars represent mean ± SD of RQ values for target proteins (IgG, ΔNp63α, and H3) in 
triplicate samples. Data are representative of two to three independent experiments. A two-
tailed, unpaired Student t-test was used to analyze the significance of the difference, *P<0.050, 
**P<0.01, ***P<0.001. 
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As shown in Fig. 25 and Fig. 26, miR-205 is transcribed along with miR-205HG and 
their transcription is reduced in the absence of ∆Np63α. We were interested in defining the 
mechanism of this transcriptional reduction. Since Pol II binds to Region 1 and potentially 
drives the transcription of miR-205HG and miR-205, we compared the binding efficiency of 
Pol II to Region 1,2 and 5 in the presence and absence of ∆Np63α. Consistent with the 
reduction in transcription determined by the nuclear run-on experiment, the binding of Pol II to 
Regions 1 and 2 significantly decreased in the absence of ∆Np63α (Fig. 29). We conclude that 
∆Np63α plays an important role in recruiting Pol II to the promoter of miR-205HG to initiate 
transcription. 
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Figure 29: Pol II binding to miR-205HG is abrogated in ∆Np63α KD cells. Real time PCR 
results of ChIP experiments demonstrate the reduction of Pol II binding to both region 1 
(promoter region) and region 2 (regulatory region) of miR-205HG and miR-205. RQ values of 
Pol II binding to regions 1, 2 and 5 were normalized to RQ values of Pol II binding to the 
GAPDH promoter. Bars represent mean ± SD of normalized RQ values in triplicate samples. A 
two-tailed, unpaired Student t-test was used to analyze the significance of the differences, 
*P<0.050, **P<0.01, ***P<0.001. 
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6. High miR-205 expression correlates with adverse clinical outcome 
The ultimate goal of translational cancer research is to benefit cancer patients by 
increasing survival and eliminating recurrence. Besides searching for a way to enhance the 
efficiency of current therapy, identifying new markers to facilitate diagnosis and new targets 
for new therapy is also an important aspect of cancer research. We reported that ∆Np63α is a 
marker of poor prognosis in MIBC in a previous publication (145). We were also eager to 
know the relationship between miR-205 expression and survival given that the data 
demonstrated that miR-205 is a downstream target of ∆Np63α. Using the qRT-PCR results 
obtained previously (Fig. 16), we compared the miR-205 expression of the 98 BC patients with 
their survival. Samples from this cohort of patients had been used in our previous study (145). 
Follow up data on survival of patients were classified into overall survival (OS) which is the 
percentage of patients who are still alive for a certain period of time after diagnosed with BC 
and disease specific survival (DSS) which is the percentage of patients who have not died from 
BC in a certain period of time. Regression tree analyses were performed by a professional 
statistician to determine the cutoff point of miR-205 expression as 1.76. Kaplan Meier curves 
were generated to examine the relationship between miR-205 expression and survival rates. In 
the whole cohort of patients (n=98, superficial plus muscle invasive), low miR-205 expression 
(≤1.76) correlated with media DSS of 140+ months and median OS of 69.1 months, whereas 
high miR-205 expression (≥1.76) was associated with significantly worse DSS and OS, with a 
median DSS of 13.4 months and a median OS of 12 months (p<0.0001 for DSS and p=0.0004 
for OS) (Fig. 30A). We also characterized the relationship in the MIBC subset of patients 
(n=66) and observed an even more remarkably result. MIBC patients with low miR-205 
expression had the median DSS of 140+ months and OS of 69.1 months while those with high 
miR-205 expression had a median DSS and OS of only 8.11 months (p<0.0001 for DSS and 
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p<0.0001 for OS) (Fig. 30B). These data prove the substantially significant correlation between 
high miR-205 expression and adverse clinical outcomes, especially for the MIBC subset 
Therefore, like ∆Np63, high miR-205 expression identifies the lethal BC subset.  
 
Figure 30: High miR-205 expression correlates with poor survival. “Kaplan-Meier 
disease specific survival (DSS) and overall survival (OS) curves generated based on the 
RT-PCR results of mature miR-205 expression in the primary tumors. (A) DSS and OS 
of the whole cohort including superficial and muscle invasive cancers (n=98). High 
expression of miR-205 was associated with poor probability of DSS and OS (median 
DSS 13.4 months, median OS 12 months), as compared to lower miR-205 (median DSS 
>140 months, median OS 69.1 months), log-rank p<0.0001 for DSS and p=0.0004 for 
OS. (B) DSS and OS for the subset of patients with muscle-invasive cancer (n=66). 
Patients with elevated miR-205 had worse clinical outcomes (median DSS 8.11 months, 
median OS 8.11 months) than patients with low miR-205 (median DSS >140 months, 
median OS 69.1 months).” Reprinted from (203) 
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CHAPTER 4: 
DISCUSSION 
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1. Summary of the findings 
In summary, our data demonstrate the important role of ∆Np63α in inhibiting EMT in 
BC. As ∆Np63α is the most abundant isoform of p63 in BC, the effect of ∆Np63α on EMT 
represents the effect of all p63 isoforms. One mechanism by which ∆Np63α inhibits EMT is 
regulating the expression of miR-205, a well established negative regulator of ZEB1 and ZEB2, 
because up- or down-regulation of ∆Np63α results in parallel changes in miR-205 levels and 
reciprocal effects on ZEB1 and ZEB2 expression, morphological alteration, and invasion. We 
also reveal, for the first time, that ∆Np63α binds to a highly conserved regulatory region of 
miR-205HG, influences the recruitment of RNA Pol II to the promoter of miR-205HG to 
regulate the transcription of miR-205HG as well as miR-205 which is transcribed along with its 
“host” gene. Interestingly, we also discovered that miR-205 expression is well correlated with 
poor clinical outcomes in BC patients, especially in MIBC patients. A similar (but weaker) 
correlation was discovered previously with p63 expression (145). These data suggest that miR-
205 and p63 can be used as markers for the lethal subset of BC patient. Moreover, since miR-
205 is a downstream target of p63, the p63 pathway can be a signature of this lethal BC subset. 
 
2. ∆Np63α partially induces EMT 
Interestingly, in 2011, Oh et al. reported that ∆Np63α promotes EMT in normal human 
keratinocytes (197). Their data also suggest that ∆Np63α triggers EMT in an TGF-dependent 
manner and provides keratinocytes with stem cell properties. In our BC cell lines, we also 
observed an induction in expression of at least one mesenchymal marker, Slug (SNAI2), in all 
∆Np63α KD cell lines and a reduction in Slug expression in ∆Np63α overexpressed UC3 cells 
(Fig.), indicating that ∆Np63α does have some EMT-promoting effects. However, the EMT-
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promoting effects of ∆Np63α-dependent Slug expression on cellular morphology and invasion 
appear to be overwhelmed by the anti-EMT effects of ∆Np63α in BC. This discrepancy in 
EMT-related effect of ∆Np63α could be due to the difference in cell type models used in the 
two studies, emphasizing the cell type dependent effects of ∆Np63α. 
 
3. MiR-205 is only one explanation for EMT 
The effect of ∆Np63α modulation on cell morphology, invasion and the expressions of 
EMT markers in BC cell lines clearly demonstrate ∆Np63α as an inhibitor of EMT. The 
signaling cascade ∆Np63α-miR-205-ZEB1/2 is one mechanism by which p63 regulates EMT in 
BC. This signaling cascade was also validated as an EMT inhibition mechanism in prostate 
cancer in a recent publication (204). In this paper, by using an approach similar to ours, the 
authors demonstrated that modulation of ∆Np63 expression by siRNA or overexpressing vector 
resulted in down or up-regulation of miR-205, respectively, and an inverse effect on ZEB1. 
They also showed that ∆Np63 overexpression inhibited cell migration and that inhibition of 
miR-205 in ∆Np63 overexpressed cells overcame the migration inhibition by ∆Np63. However, 
provided that p63 has multiple downstream targets that may involve in multiple different 
signaling pathways, it is possible that ∆Np63α inhibits EMT via mechanisms other than or in 
addition to the transcriptional regulation of miR-205. Future studies should be designed to 
explore those mechanisms. 
 
4. TAp63 and Dicer 
It is well established that ∆Np63 and TAp63 can share the same downstream targets but 
exert opposite effects by virtue of Np63‟s ability to directly compete for TAp63 target 
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promoters or by sequestering TAp63, forming inactive tetramers (205,206).  Using a knockout 
mouse model, Su et al. showed that TAp63
+/-
 and TAp63
-/-
 mice develop spontaneous 
carcinomas and sarcomas which were highly metastatic. Interestingly downregulation of Dicer 
mRNA and protein expression was observed in metastatic mouse and human tumors deficient 
in TAp63. Since Dicer is a crucial molecule in miRNA processing, decreased Dicer expression 
generates a global decrease in mature miRNA expression represented by miR-130b, miR-34a, 
miR-10b, miR-200b, and miR-200c. Their study strongly demonstrated that TAp63 regulates 
the transcription of Dicer and suppresses metastasis (171). Provided that the panp63 shRNA 
construct used in our study can diminish the expression of all p63 isoforms including TAp63 
and ∆Np63, there was a possibility that the effects on miR-205 and EMT we observed in BC 
were by loss of TAp63-regulated Dicer expression. However, in our BC cell lines, the panp63 
shRNA produced no changes in Dicer mRNA expression (Fig. 31A), and in fact it actually led 
to increased miR-200c expression in the UC14 cells (Fig. 31B). The endogenous expression 
level of TAp63 is very low in all of our BC cell lines, strongly suggesting that its effects are in 
general insignificant. In addition, modulation of ∆Np63α results in the parallel changes in miR-
205HG and miR-205, strongly suggesting that DNp63 plays an important role in the generation 
of the pri-miR-205, not at the miRNA maturation step. In general, our data describing the role 
of ∆Np63α in EMT in BC do not contradict to previous findings (171). 
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Figure 31: ∆Np63α does not affect Dicer transcription. (A) qRT-PCR results showing the 
changes in the expression of panp63, ∆Np63, TAp63 and pri-miR-205, but not Dicer when 
panp63 is knocked down in UC6 and UC14. (B) Upregulation of miR-200b in UC14 
∆Np63αKD cells. Bars show the RQ of gene expression ± RQ max and RQ min. 
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5. p53, p73 and p63 in the p53REs 
p63, p53 and p73 belong the one transcription factor family due to the homology in 
their sequence and structure. This homology allows the family members share many same 
targets and regulate transcription together. Since the p63 binding site in Region 2 contains a 
p53RE, the experiments described to this point did not rule out the possibility that p53 and/or 
p73 could also bind to Region 2 to regulate the transcription of miR-205. Indeed, p53 was 
reported to directly bind to Region 2 (as determined by ChIP and Electrophoretic Mobility Shift 
Assay (EMSA)) and regulate the transcription of miR-205 in triple negative breast cancer cells 
(207). Therefore, we performed ChIP using an anti-p53 antibody in UC6, which has WT p53 
(208). Primers detecting the promoter of p21, a canonical target of p53, were used as a positive 
control. Interestingly, we did not observe any enrichment of p53 binding in Region 2 (Fig. 32). 
Moreover, the mutation status of p53 did not correlate with expression of miR-205 (or for that 
matter, members of the miR-200 family) in our BC cell lines. For example: UC6 has WT p53 
and high expression of miR-205; however, UC11 also has WT p53 but miR-205 expression in 
UC11 is very low. Another example is that UC14 has mutant p53 but also has high expression 
of miR-205 (208). The transcriptional regulation of miR-205 by ∆Np63 was confirmed in two 
studies in prostate cancer (204,209). In both studies, ∆Np63 was shown to bind to Region 2, 
similar to our finding.  
Lack of p53‟s binding in Region 2 of miR-205 is very intriguing providing that the 
whole-site p53RE locates in this region. A possibility is that ∆Np63α, which is abundant in 
UC6, plays a major role in binding to and regulating the expression of miR-205 in normal 
unstimulated condition; however, in stimulated condition that triggers the activity of p53, such 
as DNA damage condition, p53 may target miR-205. This hypothesis needs to be proved in 
future experiments. 
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Figure 32: p53 does not bind to Region 2. Real time PCR data from ChIP experiment shows 
no enrichment of p53 binding to Region 2 and Region 5 compared to IgG negative control. A 
small enrichment of p53 binding was detected in Region 1; however, this enrichment is 
minimal compared to the enrichment of p53 binding to the promoter of p21, the positive 
control. Bars represent mean ± SD of RQ values for p53 in triplicate samples 
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6. ∆Np63 and clinical outcomes 
Despite the association of miR-205 and poor survival in MIBC, we do not believe that 
miR-205 drives the biology of bladder cancer lethality. Instead, it appears that ∆Np63, the 
upstream regulator of miR-205, is the master regulator of this lethal phenotype and miR-205 
serves as a downstream marker of ∆Np63 activity. Evidence supporting this conclusion is from 
an on-going study in which we are trying to classify MIBC in to subsets based on unsupervised 
hierarchical clustering of gene expression profiling data. The idea for this study comes from the 
fact that MIBC patients respond differently to therapy, indicating the difference in the original 
nature of MIBC in each patient. This observation is also true for many other types of cancer 
and a typical example is breast cancer which has been classified into five subtypes: normal-
like, luminal A, luminal B, HER2-enriched and basal-like (210,211). By using the same 
approach with the study in breast cancer (211), we have characterized primary tumor samples 
from 73 MIBC patients, the majority of whom had not been exposed to any type of cancer 
treatment, and discovered that these samples clustered into three discrete subsets. This result 
has been confirmed in three other independent gene expression profiling datasets. Interestingly, 
the subset that correlates with the worst clinical outcomes has an enrichment of ∆Np63‟s 
downstream targets, including the urothelial basal cell markers CK-5 and CK-14 (212,213) and 
P-cadherin. Together with the correlation between ∆Np63, miR-205 and poor survival, these 
new data confirm the enhancement of the p63 signaling pathway in the lethal subset of MIBC. 
One interpretation for our findings is that ∆Np63himiR-205hi cells in this lethal subset of MIBC 
display a basal-like phenotype because they originated from the basal layer of urothelium. 
Therefore, they potentially also possess the stem cell phenotype that support cancer 
progression, metastasis and drug resistant. The other two subsets associate with better clinical 
outcomes because, potentially, they arise from independent and more well-differentiated 
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progenitor cells. Our data and our interpretation are consistent with other studies in BC from 
different groups of researchers. They also discovered the differentiation hierarchy in BC and 
reported CK-5 and CK-14 as markers of the basal subtype and poor clinical outcome (110,117). 
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CHAPTER 5: 
FUTURE DIRECTIONS 
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1. Determine p63 isoform/isoforms binding to region 2 
Since p63 isoforms share the same DNA binding domain, they all potentially have the 
ability to bind to region 2. Even though Np63α is the most abundant isoform in BC, other p63 
isoforms still exist in BC. Therefore, we would perform ChIP to examine p63 binding to the 
miR-205 promoter using antibodies specific for TA-, ∆N-, α, β and γ isoforms of p63. The 
results of this experiment would help us to determine the specific isoforms involved in 
regulating miR-205 and/or miR-205HG. 
 
2. Determine how ∆Np63α promotes the recruitment of RNA Pol II to the promoter of 
miR-205HG 
Similar to many other miRNAs, miR-205 is transcribed along with it “host” gene and 
∆Np63 is somehow involved in the recruitment of RNA Pol II to the promoter of miR-205HG 
to regulate the transcription of miR-205 and miR-205HG. However, in contrast to its clear 
binding to region 2, our ChIP results strongly suggest that Np63α does not interact directly 
with the miR-205HG 5‟ proximal promoter. How p63 binding to Region 2 (located 2.5kb 
downstream of the transcription start site of miR-205HG) affects the binding of Pol II to 
Region 1 remains elusive. One possibility is that Region 2 is an enhancer for miR-205HG. The 
structure of chromatin in this region might bring the ∆Np63α that is bound to region 2 close to 
the proximal promoter of miR-205HG and affect Pol II recruitment. The sterile α motif (SAM) 
residue located at the C-terminus of ∆Np63α facilitates protein-protein interactions by forming 
both homo- and hetero-oligomers (214-216). Huang, Y. et al. demonstrated that ∆Np63α 
interacts with the C-terminal domain (CTD) of RNA Pol II via its SAM domain and that 
mutation of the SAM domain significantly hampered the interaction between ∆Np63α and 
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RNA Pol II CTD (217). In addition, despite lacking TA domains, the Np63 isoforms are still 
able to transactivate downstream targets due to a second TA domain located in their N-termini 
(151,152). However, the transactivating efficiency and target selectivity of this additional 
transactivation domain is still undetermined. We hypothesize that ∆Np63α recruits RNA Pol II 
to the promoter of mir-205HG via its SAM domain and participates in activating the 
transcription of miR-205HG via its secondary TA domain. We would perform co-
immunoprecipitation (Co-IP) to determine the interaction between ∆Np63α and RNA Pol II 
CTD. We would also overexpress WT, mutated forms ∆Np63α with truncated SAM domain at 
the C-terminus, and/or truncated TA domain at the N-terminus in UC3 and determine their 
ability to interact with RNA Pol II CTD by Co-IP, their ability to recruit RNA Pol II to the 
promoter of miR-205HG by ChIP, as well as their ability to activate transcription by nuclear 
run-on.  
The three dimensional conformation of chromatin in the nucleus may bring two or more 
chromatin domains that appear distant in the linear structure together in close spatial proximity, 
facilitating functional interactions among proteins bound at regulatory sites that are far apart in 
term of genomic distance to mediate transcriptional control (218,219). The p63 binding site on 
miR-205 located about 4kb away from the promoter region of miR-205HG could be brought to 
the promoter of miR-205HG in the higher order chromatin structure. To prove this hypothesis, 
we would perform chromatin immunoprecipitation – chromosome conformation capture (ChIP-
3C) using a ∆Np63-specific antibody. This technique combines the traditional ChIP and 3C 
assays (Fig. 33), in which chromatin is formaldehyde cross-linked, fragmented by sonication, 
ChIP enriched, and “proximity ligated” to capture spatially related DNA fragments, which are 
then detected by site-specific PCR. This technique has been used to study chromatin looping as 
a mechanism by which important transcription factors mediate transcription (220-222).  
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Figure 33: Schematic illustration of chromatin conformation capture (3C) (top) and 
chromatin immunoprecipitation-chromatin conformation capture (ChIP-3C) (bottom). 
Adapted from Fullwood, M. J., and Ruan, Y. J., Cell Biochem 107, 30-39 (2009) 
 
3. Determine whether ∆Np63α facilitates splicing of miR-205HG 
How ∆Np63α binding to region 2 promotes miR-205 expression is another question that 
remains unresolved. Moreover, since miR-205 is located within miR-205HG, how miR-205 is 
separated out of the “host” gene to go through the maturation process is also an interesting 
research topic. Although it is formally possible that ∆Np63α controls miR-205 transcription via 
an intragenic promoter that is regulated in parallel with the miR-205HG promoter, we do not 
favor this hypothesis, because RNA Pol II binding to region 2 appears to be much weaker than 
binding to region 1. Instead, we currently favor the idea that miR-205HG‟s promoter also 
serves as the promoter for miR-205 and that ∆Np63 promotes miR-205 expression via co-
transcriptional splicing. A role for ∆Np63α in splicing was first proposed by Fomenkov et al. in 
2003 (223). These authors showed that ∆Np63α bound to apobec-1-binding protein-1 
(ABBP1), a member of the RNA processing machinery, via the SAM domain. This interaction 
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affected the mRNA processing step of FGFR-2 and resulted in an alternative splicing toward 
the K-SAM isoform. Mutation of the SAM domain of ∆Np63α abrogated the ∆Np63α-ABBP1 
interaction and altered the FGFR-2 splicing process. In a follow up study led by the same group 
of researchers, they demonstrated that ∆Np63α formed a trimeric protein complex with 
SRA4/Scaf4, another member of the RNA splicing machinery, and the C-terminal domain 
(CTD) of RNA Pol II (217). Mutation of the SAM domain of ∆Np63α, again, induced aberrant 
splicing of the p63 mRNA transcript, resulting in a C-terminally truncated p63. In addition, 
accumulating studies show the coupling between transcription by RNA polymerase II with pre-
messenger RNA processing reactions, such as 5‟-end capping, splicing and 3‟-end formation 
(224,225). These lines of evidence lead us to hypothesize that ∆Np63α binding to region 2 
recruits the spicing factors ABBP1 and/or SRA4/Scaf4 to facilitate splicing out pri-miR-205.  
To prove this hypothesis, we would first perform ChIP for ABBP1 and SRA4/Scaf4 
followed by Co-IP to determine whether ABBP1 and/or SRA4/Scaf4 form a complex with 
∆Np63α at region 2. It was reported that the SAM domain of ∆Np63α is critical for the 
interaction between ∆Np63α and ABBP1 as well as SRA4 (217,223). Therefore, we would 
screen our BC cell lines for expression of ABBP1 and SRA4 and then overexpress the WT 
∆Np63α or a mutated form of ∆Np63α missing SAM domain together with ABBP1 and/or 
SRA4 in the cell line with low expression of panp63, ∆Np63α, ABBP1, SRA4, miR-205 and 
miR-205HG and compare the protein-protein interaction efficiency between these proteins by 
Co-IP to demonstrate the importance of SAM domain in these interactions. The next step 
would be to examine the role of ∆Np63α in miR-205HG‟s splicing. We would overexpress the 
WT and mutant forms of  ∆Np63 and measure the expression of miR-205HG, pri-miR-205 and 
mature miR-205, comparing the results among the overexpressed samples to identify the role of 
∆Np63α, ABBP1and/or SRA4 in miR-205HG‟s splicing. The primers for miR-205HG would 
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be designed to flank the junction between exon 1 and 2 (HG1-2), exon 2 and 3 (HG2-3), exon 3 
and 4 (HG3-4). The primers for pri-miR-205 would be within exon 3 of miR-205HG and 
located around 100bp upstream of miR-205 sequence. 
 
4. Determine whether ∆Np63α is dynamically regulated during MIBC progression and 
metastasis 
p63 is a master regulator of epithelial development. Because of its crucial role in 
epithelial cells, we consider p63 to be a prototypic epithelial marker. By virtue of its ability to 
suppress ZEB1/2 expression, miR-205, a downstream target of ∆Np63, is also a typical 
epithelial marker. Our data demonstrating that ∆Np63α inhibits EMT, suppresses invasion and 
maintains the epithelial phenotype, in part via miR-205, would lead one to conclude that 
Np63 would prevent tumor progression and metastasis. However, our data and our previous 
findings (145) also establish that there is a correlation between expression of ∆Np63 and miR-
205 and adverse clinical outcomes. This finding is paradoxical with respect to multiple 
publications in the literature documenting the importance of EMT in tumor progression and 
metastasis (26) and the observation that metastasis is invariably associated with BC mortality. 
However, for the past few years, scientists‟ view regarding the importance of the “epithelial” 
and “mesenchymal” status of cancer cells in tumor progression and metastasis have changed 
dramatically. Even though EMT contributes to invasion, metastatic dissemination, and stem 
cell properties, it is inevitable that metastases are epithelial and in this regard resemble primary 
tumors. Therefore, with respect to the ability to metastasize, being “epithelial” or 
“mesenchymal” is not as critical as being able to flexibly transform from one state to the other 
under environmental selection pressure. Metastatic epithelial cancer cells can acquire 
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mesenchymal traits via EMT to escape from the primary tumor site, circulate in the blood 
stream and attach to lymph nodes and distant organ, but then they appear to undergo 
“mesenchymal-to-epithelial transition” (MET) to return to their original epithelial status when 
they colonize metastatic sites. This flexibility of metastatic cancer cells is known as cancer 
“plasticity” (2). An elegant study using a carcinogen-induced squamous cell carcinoma mouse 
model convincingly demonstrated the importance of plasticity of cancer cells in vivo (74). This 
mouse model carries a skin-specific TWIST Tet-on inducible construct that was activated 
locally by topical application of doxycycline (dox) or systemic dox exposure by providing the 
drug in the drinking water. Results from this study showed that local induction of TWIST 
promoted EMT which facilitated tumor dissemination into blood circulation, forming 
circulating tumor cells (CTC), and causing extravasation. However, metastasizing tumor cells 
remained dormant at distant organs unless EMT was reversed by turning off TWIST. Reversion 
of EMT supported metastases formation by promoting cancer cell proliferation (74). 
Interestingly, ∆Np63α appears to have opposite properties to those of TWIST in BC: ∆Np63α 
inhibits EMT and promotes proliferation (189) Moreover, ∆Np63α appears to sustain 
“stemness” in epithelial cancer cells (179), and these effects probably also contribute to 
∆Np63α‟s role in supporting the colonization step of the metastasis cascade. As a result, it is 
possible that ∆Np63α is dynamically regulated during the whole metastasis process in 
metastatic cancer cells. If it is the case, the cancer cells that successfully escape from the 
primary tumor site to enter the blood circulation (CTCs) should have lower ∆Np63α expression 
than do cells in the primary tumors or cells in metastatic lesion.  
 Our future studies are designed to test this hypothesis in preclinical mouse models 
and in BC patients.  Since deletion of both p53 and PTEN promotes MIBC (129), we will 
generate transgenic mice carrying the transgenes with LoxP flanking p53 and PTEN 
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(p53
flox/flox
;PTEN
flox/flox
). These transgenic mice will have deletion of p53 and PTEN in the 
urothelium of the bladder when we surgically delivered an adenovirus expressing Cre 
recombinase into the bladder lumen. We will also generate ∆Np63α Tet-off inducible mice that 
show inhibition of ∆Np63α expression upon doxycycline (dox) treatment. ∆Np63α Tet-off 
mice will be crossed with p53
flox/flox
;PTEN
flox/flox
 mice to create the transgenic mouse model in 
which the expression of ∆Np63α, p53 and PTEN can be modulated. By delivering Cre 
Adenovirus into the bladder lumen, we induce the formation of MIBC. After the tumors are 
formed, mice will be separated into three groups. One control group that does not receive dox 
will have unmodulated ∆Np63α expression. One group which receives dox by injection into the 
bladder lumen will have ∆Np63α inhibition in tumor cells restricted in the bladder. The other 
group which receives dox in drinking water will continuously have ∆Np63α inhibition in tumor 
cells even when tumor cells migrate out of the bladder and disseminate throughout the body. 
Comparing the metastasis incidence and the rate of metastasis formation among these two 
experimental groups and the control group will demonstrate the importance of ∆Np63α in 
metastasis as well as the regulation of this protein throughout the metastasis process. 
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